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The integrity of an arterial wall is impacted by various genetic, environmental, and 
physiological factors that predispose to intracranial aneurysm (IA) formation in certain 
individuals. In this study, whole exome sequencing was completed on a large cohort of families 
from the Newfoundland and Labrador population to identify genetic predispositions contributing 
to IA development. With the use of Sanger sequencing, HAL (c.959C>T; p.T320M) emerged as a 
favourable candidate variant, and morpholino mediated gene knockdown of hal in Danio 
rerio (zebrafish) demonstrated a dose-dependent hemorrhagic phenotype. The re-expression of 
wildtype HAL RNA in the hal morpholino background was able to rescue the hemorrhagic 
phenotype while mutant HAL RNA was not. These results suggest that the HAL (c.959C>T; 
p.T320M) variant could be contributing to IA development in Family R1262. Additional analysis 
of the HAL gene could help determine the extent of its involvement and contribute to an 





Intracranial aneurysms (IA) are frequently not detected as many individuals do not 
experience symptoms until the aneurysm ruptures. Ruptured aneurysms often have devastating 
clinical outcomes that may have been preventable if the aneurysm was discovered earlier. Here, 
we aimed to identify genetic components contributing to IA development in families from 
Newfoundland and Labrador. By DNA sequencing, we identified five candidate genes that 
potentially contributed to IA development. In order to help determine if any of these genes cause 
IA, we used a zebrafish model organism to study these genes as we cannot study them in humans 
directly. The loss of function of one gene in particular (HAL), caused significant hemorrhages to 
occur in zebrafish embryos. Our results suggest that the HAL gene could be involved in IA 
development in a family from Newfoundland and Labrador. Additional studies are required to 
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1.1 Intracranial Aneurysms 
Intracranial aneurysms (IA) are thinned pouches of the arterial wall frequently found at the 
bifurcation of arteries in the Proximal Circle of Willis 1. Unruptured IAs affect 3-5% of the 
general adult population, however, our knowledge of the exact steps in IA development has yet 
to be solidified 2,3. There are various environmental, physiologic and genetic risk factors that 
predispose to IA in specific individuals, but IAs are approximately twice as likely to develop in 
females and are more common in patients over 50 years of age 3,4. A major concern of IAs is that 
they are frequently asymptomatic and consequently not detected until they rupture 5. A ruptured 
IA can lead to bleeding in the subarachnoid space, and these subarachnoid hemorrhages (SAH) 
are frequently fatal. During an initial SAH, there is a 30% death rate, and those that do survive 
often have severe neurological deficits as a result 1. Vasospasm of cerebral vessels and a 
neuroinflammatory response, with the recruitment of cytokines and immune cells, have been 
associated with the significant morbidities post SAH 6–8. Females experience a higher incidence 
and mortality rate of SAH, but the functional outcomes of those that survive is similar regardless 
of sex 9,10. The vast majority of IAs that develop are considered saccular or berry-shaped IAs and 
thus are the focus of this thesis (Figure 1.1). Fusiform IAs, which involve dilation on all sides of 
a blood vessel and dissecting IAs, where a longitudinal tear in the vessel wall traps blood 


































1.1.1 Pathophysiology  
 Despite various efforts, no definite mechanism for IA development has been completely 
agreed upon 12. The structure of a typical cerebral artery can be divided into three concentric  
layers, the tunica intima, tunica media, and tunica externa. Located closest to the vessel lumen, a 
thin layer of endothelial cells, and a well-developed, thick internal elastic lamina constitutes the 
tunica intima (Figure 1.2) 13. An external elastic lamina is characteristic of other arteries 
throughout the body, but the absence of this layer in cerebral arteries is a distinguishing feature 
14. The middle segment of a cerebral artery is the tunica media and consists mainly of tight 
bundles of vascular smooth muscle cells (VSMC) 13,15. Much of the structural integrity of the 
artery wall originates from this layer. VSMCs, as the primary cellular component, have been 
shown to play a significant role in aneurysm formation 16. The tunica externa is the thin, 
outermost layer of the arterial wall and contains mostly collagen fibers, fibroblasts, and white 
blood cells 13. In comparison to the structure of a typical cerebral artery, the vessel wall in IA is 
markedly different. The tunica media experiences significant atrophy, and thus, the composition 
of the vessel wall is predominantly externa and intima 17–19. The internal elastic lamina is also 
impacted during IA development. This component of the vessel wall may be disrupted or absent 
completely 19,20. 
Identifying arterial bifurcations as a frequent location for IA development prompted 
researchers to take a closer look at the hemodynamic stress within arterial junctions. A 
dysfunction in the endothelial cell layer as a result of hemodynamic stress marks the first step in 
IA formation 21. The increased amount of wall shear stress at arterial bifurcations is a significant 
factor in their development 22,23. Meng et al. (2007) demonstrated this by constructing new 
arterial bifurcations in the carotid vasculature of female dogs and observing the vessel  
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Figure 1.2. Pathogenesis of IA formation in tunica media of cerebral artery 
Used with permission from Zhang et al. (2019)  
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remodelling 24. The exact order of events that occur after endothelial cell dysfunction remains 
unclear, yet the role of VSMCs is widely accepted. Concentrated in tight bundles within the 
tunica media, VSMCs are the predominant source of collagen fibers and contribute significantly  
to the structural integrity of the arterial wall 20,25. An inflammatory cascade ensues during IA 
formation causing phenotypic modulation of VSMC 26. A recent study has demonstrated that 
phenotypic modulation is triggered by tumor necrosis factor alpha (TNF-α) induced down 
regulation of contractile genes. The result of this phenotypic modulation is pro-inflammatory 
VSMCs that move from the tunica media to the inner intima, where they are no longer 
compacted but proliferate and dissociate 25. Restructuring of the extracellular matrix ensues as 
the ability of VSMCs to synthesize collagen is impaired, and matrix metalloproteinase (MMP) 
production is stimulated 15,20.  The combination of impaired collagen synthesis and increased 
MMP expression would likely lead to a reduction in the strength of the vessel.  
Activation of inflammatory cells such as lymphocytes, monocytes, and macrophages is 
another widely recognized, critical pathway in IA formation. Studies have demonstrated the 
infiltration of inflammatory cells, especially macrophages, in the cerebral aneurysm tissue of 
both rats (drug induced IA formation) and humans 27–29. Human cerebral tissue was collected 
during aneurysm repairs and from post-mortem samples. Furthermore, pharmacological 
depletion of macrophages has shown a reduced incidence of IA in a mouse model (IA formation 
induced with elastase and angiotensin II), emphasizing the role of macrophages in IA 
development 30. In addition to the MMPs synthesized by VSMCs, leukocytes are also significant 
contributors to MMP production. 20,31.  The up-regulation of MMPs has a considerable effect on 
both the extracellular matrix and the internal elastic lamina. Many extracellular matrix proteins 
are known substrates of MMPs. Aoki et al. (2007) demonstrated that MMP-9 and MMP-2 play a 
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role in the degradation of the extracellular matrix components, elastin, and collagen, respectively 
28. The study also demonstrated that the progression of cerebral aneurysm formation could be 
prevented by selectively inhibiting MMP-9 and MMP-2 in a Sprague-Dawley rat model (drug 
induced IA formation). In situ hybridization has shown MMP-2 expression in blood vessels 
within the head and trunk of zebrafish 32,33. Further supporting the role of MMPs in IA 
development, a recently published genetic association study and meta-analysis found an 
association between a single nucleotide polymorphism (SNP) thought to influence the MMP-2 
gene’s transcription levels and IA (Figure 1.2) 34.  
Although hemodynamic stress marks the initial step in aneurysm formation, wall shear stress 
alone is not solely responsible for IA development. Instead, an imbalance between the integrity 
of the artery wall and the hemodynamic stress within the artery leads to a weakening of the 
arterial wall 20. The integrity of the arterial wall is impacted by various genetic, environmental, 
and physiological factors that predispose to IA formation in certain individuals 35.   
 
1.1.2 Risk Factors 
1.1.2.1 Environmental Risk Factors 
It has been well established that non-modifiable risk factors for IA development include 
female sex and an age greater than 50 years old 35,36. The prevalence of IA is rare in children and 
is highest in the fifth and sixth decades of life. Numerous modifiable risk factors can lead to de 
novo IA development, increase the risk of growth in a pre-existing IA, or increase the risk of IA 
rupture. Cigarette smoking increases the risk of developing IA, may hasten the growth of a pre-
existing IA and increase the risk of SAH 35. A case-control study by Feng et al. (2018) evaluated 
381 cases of IA and found that current smokers had a significantly increased risk of IA rupture 
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compared to both non-smokers and previous smokers 37. There is an increased prevalence of IA 
and an increased risk of SAH in individuals with hypertension and excessive alcohol 
consumption. These individuals also have an increased risk of aneurysm rupture 36,38,39. Can et 
al. (2018) found that only current alcohol use is significantly associated with IA rupture and does 
not persist in individuals with a history of alcohol abuse, thus highlighting the importance of 
alcohol cessation amongst an IA diagnosis 40.  In addition to smoking, hypertension, and alcohol, 
the risks associated with oral contraceptive use has also been explored. However, the evidence 
remains inconclusive 36.     
 
1.1.2.2 Physiologic Risk Factors 
Other well-established risk factors contributing to the risk of IA rupture are size and 
location. Large IAs that are greater than 7 mm in diameter have a significantly higher risk of 
rupture 41,42. Various studies have also suggested that IAs located in the anterior communicating 
artery or posterior communicating artery are at greater risk of rupture 41–43. Composed of the 
interconnected anterior cerebral artery, anterior communicating artery, posterior cerebral artery 
and posterior communicating artery, the anatomical configuration of an individual’s circle of 
Willis varies (Figure 1.3). With 85% of IAs originating in the proximal circle of Willis, 35% of 
which are located in the anterior communicating artery, understanding the significance of this 
arterial structure is essential 11. The possibility an individual’s circle of Willis configuration is 
heritable has also been explored. van Kammen et al. (2018) examined the circle of Willis 
architecture in two unrelated families with a history of intracranial aneurysms. They found that 
the incomplete posterior communicating artery configuration was more likely to occur within 





Figure 1.3. Circle of Willis anatomy in cerebral vasculature 
The circle of Willis includes the anterior cerebral artery, anterior communicating 
artery, posterior communicating artery, and posterior cerebral artery 
 






increased risk of cerebral aneurysm rupture in patients who have an asymmetrical circle of Willis 
configuration 45. The configuration with the strongest link to aneurysm rupture was 
hypoplasia/aplasia of the A1 segment of the anterior cerebral artery in an asymmetric circle of 
Willis 45. As suggested, identifying anatomic characteristics that may predispose to an increased 
risk of aneurysm rupture could influence the future management plan for patients with 
unruptured aneurysms 45.  
 
1.1.2.3 Genetic Risk Factors 
Considerable efforts have attempted to piece together the genomic contribution to IA 
development as estimates suggest that up to 25% of IAs have an underlying genetic component 
46. An individual’s risk of developing an IA increases by seven times if a first-degree relative has 
had an IA 46. Despite significant advancements, there is still a lot to learn about the genomic 
contribution to IA. There is a strong association between IA and other vascular connective tissue 
disorders with recognized genetic contributions (Table 1.1) 46. Anywhere from 4-17% of 
autosomal dominant polycystic kidney disease (ADPKD) patients will eventually develop IA 46. 
Other hereditary Mendelian disorders that are at risk for IA development include Ehlers-Danlos 
syndrome, Marfan Syndrome, Neurofibromatosis Type 1, and Loeys-Ditz Syndrome 47. 
Investigations have found that less than 10% of IA is attributable to these disorders, and thus the 
focus of this thesis is on non-syndromic IA development 36,41.  The interplay of various 
physiologic, environmental, and genetic risk factors makes determining the source of non-
syndromic IA development challenging and further complicates decisions surrounding screening, 
diagnosis, and treatment options. 
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Table 1.1 Prevalence of IA in selected syndromes and their associated genes a 
Syndrome Associated Genes Prevalence of Patients with IAb 
ADPKD PKD1, PKD2 4 – 17% 46 
Ehlers-Danlos Syndrome COL3A1 12% 48 
Marfan Syndrome FBN1 14% 48 
Neurofibromatosis Type I NF1 9 – 11% 48 
Loeys-Ditz Syndrome TGFBR1, TGFBR2, SMAD3 11 – 28% 48 
Pseudoxanthoma 
Elasticum c ABCC6 N/A 
Hereditary Hemorrhagic 
Telangiectasia c ENG N/A 
Multiple Endocrine 




a Adapted from Hitchcock et al. (2017) (CC BY 4.0) 
b Reported prevalence estimates from some studies may include both saccular and fusiform IAs 
c Individual case reports only 
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1.1.3 Screening and Diagnosis 
 As a result of the asymptomatic nature of IA, in combination with the advancements in 
neuroimaging, the majority of diagnosed IAs are incidental findings 49. Digital subtraction 
angiography (DSA) is considered the goal-standard neuroimaging tool for unruptured IA 
diagnosis. DSA can produce a higher resolution image with excellent specificity and sensitivity. 
However, the invasive nature, higher cost, associated risks, and radiation exposure makes its use 
more appropriate when additional structural features are necessary rather than as a primary 
diagnostic tool 36,49,50. Therefore, computed tomography angiography (CTA) and magnetic 
resonance angiography (MRA) continue to be more frequently used methods 36,49. The sensitivity 
and specificity of CTA and MRA are also high for the diagnosis of IA, especially for those 
greater than 3 mm in diameter 50,51. The less invasive nature and lower costs associated with 
CTA and MRA also add to their appeal. Guidelines from the American Heart Association 
suggest that ultimately, both CTA and MRA are appropriate tools for use in unruptured IA 
detection and follow-up 36.  
 In families with two or more individuals with IA or SAH, screening of unaffected 
relatives is recommended 36. Screening recommendations are particularly important in 
individuals who have risk factors associated with IA development and a family history of IA. 
The timeline for beginning screening is ten years before the earliest age of IA diagnosis within a 
family, according to expert consensus 47. As with any screening program, it is essential to 
acknowledge the negative impact an IA diagnosis may have on a patient’s quality of life. 
Aneurysm repair is not always the most appropriate management path for IA. Quite often, 
conservative management with follow-up is used, and thus patient counseling is of the utmost 
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importance before screening 52. Furthermore, family members of individuals with sporadic IA, 
where there is no suspected familial contribution, are not recommended for screening 36.  
The higher risk of IA development in patients with heritable connective tissue disorders 
makes screening a reasonable consideration 36. The particularly strong link between IA and 
ADPKD makes screening with MRA a recommendation in these patients 36,46. A recent study by 
Flahault et al. (2018) compared the use of targeted screening in which only ADPKD patients 
with a family history of IA were screened versus systematic screening of all ADPKD patients 53. 
They found that systematic screening was, in fact, cost-effective, and a better option considering 
the high rupture rate of IA in ADPKD patients without a family history 53. There is a lack of data 
surrounding the benefits of screening in other IA associated disorders currently, and thus 
screening recommendations must be evaluated for each case individually 47.    
 
1.1.4 Management of Unruptured IAs 
The appropriate management of unruptured IAs is continuously changing. Our understanding 
of IA pathogenesis continues to evolve, and new technological advances are frequently 
occurring. Generally, there are three broad categories of treatment options that include 
conservative management, surgery, or endovascular therapy 50. The management plan for each 
unruptured IA is highly individual. Physicians must take into consideration the physiologic 
characteristics of the aneurysm, such as size, location, and morphology, in addition to patient 
characteristics such as any environmental and genetic risk factors. Deciding the best 
management protocol for unruptured IAs can be challenging, partially due to the uncertainties of 
IA pathogenesis and the numerous risk factors associated with their risk of rupture. The 
PHASES score was introduced in 2014 to aid in the clinical decision making of unruptured IA 54. 
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This risk prediction chart uses six predictors of prognosis that include population, hypertension, 
age, the size of the aneurysm, previous SAH from another aneurysm, and the site of the 
aneurysm, to predict the five-year aneurysm rupture risk. Each predictor is associated with a 
specific number of points, and the larger an individual’s total score, the higher the risk of 
aneurysm rupture 54. In 2015, the unruptured IA treatment score (UIATS) was generated as an 
additional tool to assist with unruptured IA treatment decisions 55. Unlike the PHASES score, the 
UIATS is not a predictive model, and instead, it is a scoring model generated by 
multidisciplinary specialists in the cerebrovascular field. A physician can use the model to 
determine if other specialists would support a specific management plan based on various patient 
and aneurysm characteristics 55. Most recently, a system was created to predict the three and 
five–year absolute risks for aneurysm growth 56. The ELAPSS system uses many of the same 
predictors as PHASES, except aneurysm shape is included, and hypertension is not considered. 
Evaluating the risk of growth can help physicians determine the optimal follow-up time for each 
patient. Although there are limitations associated with these systems and the management of 
each patient is highly individual, they can be used as supplemental tools when the most 
appropriate management plan is unclear 56.  
A conservative management approach is often used for smaller IAs (less than 7 mm), or 
where there is a low risk of aneurysm rupture 36,50. Extensive counseling is required for these 
patients to emphasize any modifiable factors that will increase the risk of IA rupture. The 
American Heart Association guidelines suggest that counseling should include information about 
smoking cessation, moderate alcohol consumption, and hypertension control 36. Conservative 
management also requires routine serial imaging with MRA or CTA to track aneurysm growth or 
morphological changes 36,50.  
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Surgical occlusion has long been used as a treatment option for unruptured aneurysms, with 
the first successful clipping of an internal carotid aneurysm taking place in 1937 57. Although 
other surgical techniques such as wrapping and occlusion bypass are occasionally used for 
complex aneurysms, basic aneurysm clipping is still widely used 36,49. The procedure generally 
involves the placement of a metal clip at the neck of the aneurysm during an open craniotomy 
(Figure 1.4). Complete occlusion of blood flow is the goal of treatment in order to isolate the 
aneurysm from the parental blood supply 1. The procedure is quite effective with minimal 
recurrence risk as total occlusion occurs in the majority of cases 1,58. Major risk factors  
associated with surgical management of IA involve the aneurysm size and location 36. Kotowski 
et al. (2013) found that IAs located in the posterior circulation and those with an increased 
diameter were associated with unfavorable surgical outcomes such as death and disability 15,59. 
Treatment guidelines suggest that long term follow-up should be considered post-surgery,  
especially cases of incomplete obliteration 36.  
Endovascular techniques are another treatment option for unruptured IA. Developed after 
surgical clipping, endovascular therapy provided a less invasive alternative to surgical techniques 
with quicker recovery times (Figure 1.5) 49. Although there are now several different 
endovascular techniques available such as flow diverters, liquid embolic agents, and more recent 
medical management strategies, coil embolism remains the most commonly used procedure 1,49. 
To isolate an IA from the parental artery, local thrombosis and blocking of blood flow are 
stimulated by the endovascular insertion of a coil into the aneurysm 1. To address problems with 






Figure 1.5. Endovascular coiling 
Used with permission of Mayo Foundation for Medical Education and Research, 
all rights reserved 
Figure 1.4. Aneurysm clipping 
Used with permission of Mayo Foundation for Medical Education and 
Research, all rights reserved 
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techniques like stent assistance and balloon inflation were generated 50. Numerous reviews 
suggest a high quality, large-scale, randomized clinical trial is needed to directly compare 
surgical clipping and endovascular coiling for IA management 1,15,60.  In comparison to surgical 
clipping, endovascular techniques have lower associated morbidity and mortality rates 36.  
Additional treatment may be necessary for endovascular therapies as there is a greater 
recurrence risk that should be considered 36. Guidelines from the American Heart Association 
suggest that both surgical clipping and endovascular coiling should be performed in higher 
volume centers as they are associated with better procedural outcomes 36. Regardless of the 
treatment selected, all cases of unruptured IAs are unique and must be evaluated on an individual 
basis. Treatment plans are ultimately the patient’s decision. Nonetheless, they must have all the 
necessary information, including the advantages and disadvantages of each option, to make an 
informed decision. As more information is uncovered about IA pathogenesis, hopefully, 
advancements in diagnosis, screening, and management will follow. 
 
1.2 Genetic Component 
1.2.1 Family IA Studies 
The genetic predisposition contributing to familial IA development has long been 
recognized. To gain a better understanding of how familial IA differs from sporadic cases, 
analyzing large family cohorts has been particularly useful. In 2003, a large familial IA study 
was published by Wills et al. (2003) aiming to assess the inheritance patterns of IA, which 
seemed consistent with Mendelian inheritance 61,62. The study included 346 Finnish families, 
each of which had at least two individuals affected with IA, and no other IA associated 
syndromes were present. Analysis of the 937 IA patients revealed multiple modes of inheritance. 
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The study found that IA was passed down to both sons and daughters of affected parents, thus 
indicating an autosomal inheritance pattern. With 57.2% of families demonstrating inheritance 
patterns consistent with autosomal recessive inheritance, this was the predominant pattern. There 
was also evidence of autosomal dominant inheritance in 36.4% of families, and 5.5% had 
autosomal dominant inheritance with incomplete penetrance. There was an additional 0.9% of 
families that did not align with any known inheritance pattern 61.  
The Familial Intracranial Aneurysm (FIA) study was another large, well-known study 
that utilized large family cohorts to investigate familial IA. The study was a collaborative effort 
between researchers and clinicians across North America, Australia, and New Zealand with 26 
clinical centers, 41 recruitment sites, and over 500 families enrolled 63. Broderick et al. (2009) 
used 542 families that were recruited as part of the FIA study to investigate the risk of rupture in 
familial IA. The results indicated that there is a greater risk of rupture in familial IA as compared 
to sporadic cases of similar size 64. The study published by Broderick et al. (2009) is just one 
example of countless studies that have since been published using the FIA patient cohort to help 
understand familial IA.  
  
1.2.2 Linkage Studies 
Early investigations evaluating the genetic contribution of familial IA development 
employed the use of linkage analysis. A useful tool for investigating Mendelian disorders, 
linkage studies attempt to identify the genomic location of genes that are contributing to disease 
development 65. Linkage studies use a family-based approach to evaluate the co-segregation of 
IA with known genetic markers and have been able to identify several IA susceptibility loci 66. 
The FIA study, an extensive collaborative international effort, performed a whole genome SNP 
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linkage analysis on IA families from across the globe. They first performed a linkage analysis 
midway through the study on 192 families then completed a subsequent analysis on the total 
cohort of 333 families once the genotyping was complete 67,68. The results from both studies 
demonstrated possible linkage to four chromosomal regions, with linkage to region 4q32 being 
the most evident, although not statistically significant. The lack of strong linkage detection to 
one specific chromosomal region in this study is also characteristic of other linkage analyses.  A 
recent review article by Zhou et al. (2018) summarized the loci identified via linkage analysis for 
familial IA (Table 1.2) 66. The chromosomal regions 1p34.3-36.13, 4q32, 7q11, 19q13 and Xp22 
have been validated in more than one study across multiple populations, thus increasing the 
likelihood of their relevance to familial IA.  
In 2001 the first genome-wide linkage analysis of IA was published using a cohort of 84 
families of Japanese ethnicity 69. Results identified three chromosomal regions as IA risk loci, 
5q22-31, 7q11, and 14q22. The most substantial evidence of linkage was reported near the 
marker D752472 on chromosome (Chr) 7q11. The study reported the closely positioned elastin 
(ELN) as a positional candidate IA gene due to its location and functional relevance as a blood 
vessel wall component 69. Three years later, Farnham et al. (2004) confirmed 7q11 as a risk locus 
through linkage analysis in 13 families from the United States 70.  
Shortly after the first linkage analysis to identify chromosomal regions related to IA was 
published, Olson et al. (2002) performed a similar study examining 85 Finnish families 71. 
Although there was no overlap in the loci identified, Olson et al. (2002) found chromosomal 
regions Xp22 and 19q13 to be suggestive of linkage 71. The significance of region 19q13 as an 
IA susceptibly loci was further validated in a follow-up study. In addition to confirmation of 
previous linkage, the study also defined the region on Chr 19q13 between markers D19S5454  
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Table 1.2. Risk Loci Reported in the Linkage Studies for Familial Intracranial Aneurysmsiv  
 
iv Used with permission from Zhou et al. (2018) 
Linkage Loci Populations Study Cohort: Affected/Family (LOD Score) References  
1p34.3-36.13 
North American 10/1 (4.2) Nahed et al (2005)72 
Dutch 7/1 (3.18) Ruigrok et al (2008)73 
2p13 Dutch 7/1 (3.55) Roos et al (2004)74 
4q32 FIA 
482/192 (3.5) Foroud et al (2008)67 
866/333 (2.6) Foroud et al (2009)68 
5p15.2-14.3 French-Canadian 12/1 (3.57) Verlaan et al (2006)75 
5q22-31 Japanese 104 sib-pairs (2.24) Onda et al (2001)69 
7q11 
Utah 39/13 (2.34) Farnham et al (2004)70 
Japanese 104 sib–pairs (3.22) Onda et al (2001)69 
8p22.2 Korean 13/5 (3.61) Kim et al (2011)76 
11q24-25 North American 10/2 (4/3) Ozturk et al (2006)77 
12p12.3 FIA 866/333 (3.1) Foroud et al (2009)68 
13q14-21 French-Canadian 10/1 (4.56) Santiago-Sim et al (2009)78 
14q22 Japanese 104 sib-pairs (2.31) Onda et al (2001)69 
14q23-31 North American 10/2 (3.0) Ozturk et al (2006)77 
17cen Japanese 127/29 (3.0) Yamada et al (2004)79  
19q13 Finnish 
48 sib-pairs (2.6) Olson et al (2002)71 





















41/9 (4.1) Mineharu et al (2007)81 
127/29 (2.15) Yamada et al (2004)79 
Xp22 
Dutch 7/1 (4.54) Ruigrok et al (2008)73 
Finnish 48 sib-pairs (2.08) Olson et al (2002)71 
Japanese 127/29 (2.16) Yamada et al (2004)79 
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and D19S246 to most likely harbour an IA candidate gene 80. Further evidence of linkage on Chr 
19q13 was identified in a genome-wide non-parametric linkage analysis of 29 Japanese families. 
The study identified both 19q13 and Xp22 as potentially interesting regions for familial IA 79,82. 
A follow-up study used the same cohort of Japanese families but completed a parametric analysis 
assuming autosomal dominant inheritance of IA. The results confirmed linkage between 
autosomal dominant IA in Japanese families and chromosome 19q13, suggesting this region may 
be relevant across populations 81. 
Chr region Xp22 is the only familial IA risk loci identified in three different populations 
66. Already acknowledged as an IA susceptibility locus in both Finnish and Japanese populations, 
Ruigrok et al. (2008) replicated these findings when they identified significant linkage to Xp22 
in a large Dutch family 73. They also found suggestive linkage to Chr 1p36, which had already 
been highlighted as a risk locus in a large family from North America with 11 affected 
individuals. More specifically, the region on Chr 1 initially identified is a 12.5cM segment from 
1p34.3-36.13 72. 
Linkage analysis has previously been successful in identifying disease-causing genes 
responsible for many Mendelian disorders, including Huntington’s disease and cystic fibrosis 65. 
Nevertheless, linkage analysis can be problematic as it is often difficult to extrapolate the results 
to a larger population. Refining a candidate region to a specific gene of interest can also be 
challenging 83. While many IA susceptibility loci have been identified via linkage analysis, 
clarifying which particular variants are relevant to IA development within these chromosomal 




1.2.3 Genome-wide Association Studies 
Seven years after the first linkage study of familial IA, genome-wide association studies 
(GWAS) gained appeal as an alternative methodology to study IA 84. Without specifying a 
candidate gene of interest, GWAS can provide an association between human disease and known 
SNPs by scanning the genomes of affected individuals and comparing them to unrelated disease–
free controls 66,83. Although linkage analysis has been successful in studying various monogenic 
disorders, it has been much less beneficial in more common, complex diseases. The emergence 
of GWAS provided an alternative approach that also addressed some of the limitations 
surrounding linkage analysis 85. 
The initially published GWAS for IA considered patients from Finland, Japan, and the 
Netherlands. Using these three cohorts and controls, Bilguvar et al. (2008) found two new loci 
on chromosomes 2q and 8q, and the previously highlighted region on chromosome 9q, to be 
significantly associated with IA 84. All cases of IA were confirmed via MRA, CTA or DSA. 
Control cases came from Finland, Japan, and the Netherlands, but only Japanese controls were 
screened to verify there was no IA. A follow-up GWAS by the same group conducted shortly 
after increased the number of patients in the Japanese cohort and added two additional European 
cohorts. This subsequent GWAS identified three new chromosomal regions, including 10q24.32, 
13q13.1, and 18q11.2, with strong associations to IA and furthermore confirmed the previously 
established associations with areas 8q11.23-q12.1 and most significantly 9q21.3 86. While many 
loci have been associated with IA, locus 9q21.3 has been replicated most frequently (Figure 1.6) 
47,87. This locus is located nearby the cyclin dependent kinase inhibitor 2A (CDKN2A) gene, 
which has tumor suppressor functions, and the adjacent cyclin dependent kinase inhibitor 2B 




Figure 1.6. Significant IA candidate genes discovered via GWAS 
Used with permission from Hussain et al. (2013) 
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also contains methylthioadenosine phosphorylase (MTAP) and CDKN2B antisense RNA 1  
(CDKN2B-AS). MTAP is involved in polyamine metabolism and CDKN2B-AS is a large 
antisense non-coding RNA otherwise known as ANRIL 89,90. A GWAS by Foroud et al. (2012) 
found that rather than an association to CDKN2A or CDKN2B as previously reported, the 
association between IA and 9q21.3 is more attributable to SNPs in CDKN2B-AS1 91. The 
structural complexity of this region has hindered any functional validation, and thus, its actual 
relevance to IA development is still mostly unknown 92. Furthermore, although the region 9q21.3 
has been consistently associated with IA, it has also been classified as a GWAS hot spot. Several 
other human diseases such as, coronary artery disease, type 2 diabetes, and various carcinomas,  
have been associated with this locus 89,93.  
The locus 8q11.23-q12.1, near the gene SRY-box transcription factor 17 (SOX17), was also 
associated with IA in the initial GWAS, and has subsequently been validated by other 
independent groups 84,86,91. The involvement of SOX17 in embryonic development, and more  
specifically, angiogenesis has made it a particularly noteworthy candidate in IA development 88. 
Studies investigating SOX17 have demonstrated its selective expression in the arterial endothelial 
cells of both newborn and adults mice 94,95. Furthermore, an important role for SOX17 in 
endothelial regeneration post vascular injury has been suggested 96. While initial studies found an 
association with both the 5’ and 3’ regions of SOX17, subsequent GWAS have demonstrated an 
association with only one or the other, depending on the population 84. A more recent GWAS of 
patients recruited from the FIA study found an association with only the 3’ end, whereas 
previous GWAS of Japanese populations appear to associate with the 5’ end 84,86,91. The 
recurrence of locus 8q11.23 prompted functional validation of SOX17 to evaluate its role in IA 
development further. Lee et al. (2015) demonstrated significant IA formation in a SOX17 
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deficient mouse model under hypertensive conditions as compared to controls 95. IA 
development occurred spontaneously in 25% of mice with SOX17 deletions, yet IA occurrence 
increased to 60% when systemic hypertensive stress was induced via angiotensin II infusions. 
The combination of GWAS data, endothelial expression, and functional analysis provides 
evidence to suggest SOX17 plays a notable role in IA formation 95.  
While 8q11 and 9q21.3 are the regions persistently replicated via GWAS, many other 
noteworthy loci have been significantly associated with IA. A small founder population and 
genetic drift have resulted in unique genetic variation within the French-Canadian population, 
including an increased incidence of IA 97. A recent GWAS using this population identified two 
new loci with significant IA association, 3p14.2 and 3q13.2, which encompass fragile histidine 
triad (FHIT) and coiled-coil domain containing 80 (CCDC80) genes, respectively 97. The control 
cohort consisted of primarily unrelated individuals from the French-Canadian population without 
cerebrovascular diseases, and IA cases were confirmed with MRA or during surgery. Over 40% 
of IA patients in this population also have hypertension which led Zhou et al. (2018) to 
investigate the relationship between SNPs in these genes and hypertensive IA. The results 
indicated that FHIT is predominantly associated with hypertensive IAs, as multiple SNPs in 
FHIT were found to be significantly associated with this trait. The biological relevance of the 
CCDC80 gene makes it particularly interesting due to its involvement in cell adhesion, matrix 
assembly, and wide expression in VSMCs 88,97.   
The co-occurrence of multiple aneurysm types has also prompted investigations into shared 
genetic contributions. A large meta-analysis published in 2016 analyzed GWAS data from 
previously published IA, thoracic aortic aneurysm (TAA) and abdominal aortic aneurysm (AAA) 
cases and controls. The goal was to determine any significantly shared chromosomal loci 98. 
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While no significant polygenic overlap was found, the majority of analyzed cases were sporadic 
IA. However, aneurysmal co-occurrence exists predominately in families. The study suggested 
that a shared genetic contribution may exist in familial cases, and further analysis with larger 
sample sizes are required 98. Although the various loci and candidate genes identified by GWAS 
have laid a solid foundation to help understand the genetic contribution leading to IA 
development, significant knowledge gaps remain for this complex vascular condition 47,66.  
 
1.2.4 Next Generation Sequencing 
Genetic variations that underlie several Mendelian disorders have been identified due to 
advancements in next generation sequencing (NGS) technologies 99. With the use of whole 
exome sequencing (WES), any discrepancies between the protein-coding region of an 
individual’s genome and that of the human reference genome can be identified, and conclusions 
can be formed about common genetic variants. Although the exome accounts for only 1% of the 
human genome, variants underlying Mendelian disorders are most often identified in this region 
99. The previous success of using this technique to identify candidate variants in human disease 
provided confidence that WES could also be an efficient approach to investigate IAs.  
The population recruited from the FIA study was utilized in multiple publications 
employing the use of WES. Seven families were selected from this cohort that had the greatest 
number of family members affected with IA 62. The initial study performed WES on both 
affected and unaffected individuals from the seven families, for a total of 50 exomes. The 
variants generated via WES were prioritized based on numerous filtering criteria that ultimately 
highlighted 96 candidate genes 62. The second publication analyzed sequencing data of 45 
individuals from the seven families, 36 affected, and nine unaffected relatives 100. To organize 
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the WES data, variants were prioritized that segregated with all affected family members, 
variants with a minor allele frequency (MAF) <1%, autosomal variants, nonsynonymous SNVs, 
and variants predicted deleterious by two protein prediction programs. Farlow et al. (2015) 
ultimately published a list of 68 rare variants in 68 genes that segregated with IA in at least one 
family 100. The chromosomal location of these 68 candidate genes was also compared with the 
well-established candidate IA loci previously reported in GWAS. However, there was no overlap 
identified. RNA expression data was also considered, which involved collecting IA tissue 
samples from patients undergoing surgical clipping and comparing them to vascular tissue from 
surgical patients with intractable epilepsy as a control. The only gene differentially expressed in 
IA tissue as compared to the control was transmembrane protein 132B (TMEM132B). The study 
concluded that further research into this list of candidate genes, specifically through replication 
with a larger sample size or functional analysis in an appropriate functional model, would be 
beneficial 100.  
A similar study by Yan et al. (2015) revealed new candidate genes in IA development 101. 
WES was performed on the exomes of 42 individuals from 12 families of Japanese ancestry who 
had at least three individuals affected with IA. There were 78 candidate variants identified after 
variant prioritization, which encompassed the inclusion criteria: variants shared by all affected 
family members, MAF <5%, predicted to affect the protein-coding sequence, and predicted 
damaging by two protein prediction programs. Of the 78 candidates highlighted, 10 variants 
from nine genes were selected for further investigation based on biological relevance and 
increased prevalence in IA patients. Replicate association studies used Sanger sequencing and 
examined two additional unrelated cohorts, one with familial IA cases and another with sporadic 
IA cases. The variant p.E133Q in A Disintegrin and Metalloproteinase with 
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Thrombospondin Type 1 Motif 15 (ADAMTS15), was the only variant that significantly 
aggregated in familial IA cases. Furthermore, the study showed antiangiogenic activity of 
ADAMTS15 with overexpression of the p.E133Q variant. The study suggested that while further 
replication and a functional investigation is required, ADAMTS15 has emerged as a possible 
candidate IA gene 101.  
The increased prevalence of IA in the French-Canadian population has prompted its use 
to investigate the genetic contribution to IA pathogenesis 97. In addition to the susceptibility loci 
identified by GWAS, the use of WES highlighted mutations in ring finger protein 213 (RNF213), 
as a risk factor for IA in the French-Canadian population 102. A study by Zhou et al. (2016) 
completed WES on 26 individuals with IA across six French-Canadian families. The variant 
prioritization strategy aimed to prioritize variants shared in affected individuals across multiple 
families. RNF213 emerged as the top candidate after five distinct variants within the gene were 
identified in four families. Furthermore, it was the only prioritized gene with a mutation burden 
significantly different between affected individuals and controls. Targeted sequencing in a larger 
French-Canadian cohort, and association testing by Zhou et al. (2018) further supported the 
possibility that RNF213 was contributing to IA within this particular population 97,103.  
 Yang et al. (2018) combined the data generated from the three previously described 
studies by Farlow, Yan, and Zhou in a 2018 paper that identified Rho Guanine Nucleotide 
Exchange Factor 17 (ARHGEF17) as an IA risk gene 100–102,104. The study began with whole 
genome sequencing (WGS) of twenty Chinese patients with either familial or sporadic IA 104. A 
bioinformatics based variant filtering strategy prioritized 30 candidate variants that were 
subsequently investigated in cohorts recruited from previously published studies 100–102. Of the 
30 candidate variants, six of them were also identified in the replication cohorts. ARHGEF17 
 29 
emerged as a candidate gene of interest due to its particular high mutation burden in IA cases as 
compared to controls. Using a zebrafish model, Yang et al. (2018) demonstrated significant 
ARHGEF17 expression in the head region, and knockdown of ARHGEF17 induced a significant 
intracranial hemorrhage phenotype, providing further support of its role in IA development 104.  
In contrast to the WES studies previously described that utilized cohorts of multiple IA 
families, Santiago-Sim et al. (2016) focused on one large European-American family 105. There 
were twenty-one study participants within the family, three with documented SAH, six with 
unruptured IA, and 13 unaffected relatives. WES was completed on the exomes of two affected 
family members, and after the implementation of various filtering criteria, 53 heterozygous 
variants were eventually identified 105. Santiago-Sim et al. (2009) previously published a 
genome-wide linkage analysis of the same family, which identified a region on Chr 13q as an IA 
susceptibility locus 78. After a comparison of the linkage and WES data, only one of 53 variants 
fell under the linkage peak that resulted in a truncated protein, the nonsense mutation p.R450X in 
thrombospondin type-1 domain-containing protein 1 (THSD1) 105. The p.R450X variant in 
THSD1 segregated with all affected family members and was absent from all unaffected 
relatives. Targeted sequencing of THSD1 in 507 unrelated IA probands revealed eight additional 
missense mutations. Furthermore, functional analysis of THSD1 in both zebrafish and mouse 
models resulted in cerebral bleeding, further substantiating the possibility that THSD1 is relevant 
to IA development 105.  
An additional WES study by Wu et al. (2018) focused on a smaller IA family of Chinese 
ancestry 106. There were six study participants within the family, five individuals with IA, and 
one unaffected relative. After WES of three affected individuals and the one unaffected relative, 
bioinformatic filters were implemented, and fifteen SNVs along with three indels were 
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recognized as potentially significant. The five variants deemed most functionally relevant to IA 
were then Sanger sequenced to visualize segregation within the family. One mutation segregated 
completely with all affected individuals, p.C133T in lysyl oxidase like 2 (LOXL2) 106. The 
relevance of LOX in IA development had been examined previously, but these investigations 
produced conflicting results. Sathyan et al. (2013) reported no significant association between 
LOX polymorphisms and IA in a south Indian population 107. Alternatively, associations have 
been found between LOXL2 and IA in Japanese and Korean populations 108,109. Wu et al. (2018) 
proposed that the combination of these results indicates that further functional analysis of LOXL2 
should be considered 106.  
A study by Bourcier et al. (2018) combined WES and identity by descent (IBD) analysis 
to generate a list of IA candidate variants from a family recruited as part of the French ICAN 
project 110,111. This multicenter nationwide research project recruited both familial and sporadic 
IA cases from across France, aiming to better understand the pathophysiology of IA 110. The 
family used by Bourcier et al. (2018) had five individuals affected with IA, four of which DNA 
was available from 111. Two affected family members underwent WES and IBD analysis, and 
ultimately ten common variants were highlighted. Eight of these variants were also found in the 
two other family members with IA. The only loss of function variant within those prioritized was 
c.1378A>T in angiopoietin-like 6 (ANGPTL6). This gene was previously identified as a pro–
angiogenic factor capable of increasing the permeability of the endothelium and stimulating cell 
migration 112. Bourcier et al. (2018) extended their genetic analysis to five additional IA families. 
They discovered that rare variants within ANGPTL6 were present in 92% of individuals affected 
with IA as compared to 37% of unaffected relatives. The study concluded that the results 
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generated via WES, IBD, and expression data prompt further functional analysis into ANGPTL6 
111. 
Several studies have recently been able to identify genetic contributions that are 
potentially responsible for the development of non-syndromic IA with the use of NGS 
techniques (Table 1.3). Although we have gained valuable insight using these technologies, our 
knowledge of the genetic predisposition leading to IA development is still lacking. It is 
becoming increasingly clear that one causative genetic variant is likely not responsible for IA 
development across all populations. Instead, multiple genetic contributions are more plausible. 
Future NGS studies will be beneficial in identifying additional pathogenic variants contributing 
to IA development in other families.  
 
1.3 Zebrafish – Danio rerio 
1.3.1 Functional Model of Genetic Disease 
 A common problem that arises is the vast abundance of variants generated from NGS. 
Even with extensive variant filtering pipelines, it is difficult to classify a genetic variant as 
causative. When relying on clinical data and analyzing pedigree segregation, there are many 
underlying factors to consider. External risk factors, incomplete penetrance, and potential 
phenocopies can all impact how variants are ultimately filtered. With significant advancements 
in NGS technologies and higher numbers of genetic variants being identified, the use of model 
organisms has become increasingly important. By using a model organism, the link between 
genotype and phenotype can be validated, and more accurate functional predictions can be made 
113.  
In recent years, the zebrafish has emerged as an exceptional model organism for  
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Table 1.3 Candidate IA genes identified via NGS 
  
Gene Chromosomal Position Population References 
TMEM132B 12q24.31 FIA Farlow et al. (2015) 100 
ADAMTS15 11q24.3 Japanese Yan et al. (2015) 101 
RNF213 17q25.3 French-Canadian Zhou et al. (2016 )102 
ARHGEF17 11q13.4 Chinese Yang et al. (2018) 104 
THSD1 13q14.3 European-American Santiago-Sim et al. (2016) 105 
LOXL2 8p21.3 Chinese Wu et al. (2018) 106 
ANGPTL6 19p13.2 French Bourcier et al. (2018) 111 
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investigating genetic disease. This tropical, brackish water, vertebrate belongs to the largest 
family of fish, the Cyprinidae family 114. Although the benefits of using this model in genetic 
research have come to light in more recent years, zebrafish have been used as an embryologic 
model since the 1930s 115,116.  An appealing aspect of a zebrafish model is that they address many 
of the concerns that arise with traditional animal models. They are relatively inexpensive, less 
time consuming, and less labor-intensive than a conventional model 117. Post-embryonic 
development of zebrafish occurs rapidly, and sexually mature adults are formed within 
approximately three months 118. Generating zebrafish embryos is a relatively simple process as 
laboratory breeding can occur throughout the year and does not follow a marked seasonality. 
Furthermore, their fertilization is external, and each mating pair can generate up to 300 embryos 
117,119. The small size of these fish minimizes the infrastructure required for storage but also 
allows larger-scale studies (Figure 1.7) 120. Completing studies at a larger-scale would typically 
be characteristic of only invertebrate models as space and support required to develop a large 
scale experiment in other vertebrates are quite costly and labor-intensive 116. As a model 
organism, zebrafish have been able to strike a balance between the advantages and disadvantages 
of other model organisms. Zebrafish address various practicality issues. They provide the 
affordability and feasibility associated with an invertebrate model such as a fly, while also 
providing physiologic attributes characteristic of vertebrate models that are essential to study 
human disease 116.  
Many studies have employed the use of zebrafish to investigate various vascular 
dysfunctions. The fundamental vasculature of zebrafish is similar to that of humans, and their 
transparent embryos allow for visualization of this vasculature. To investigate any hemorrhagic 
phenotype, this provides a non-invasive approach to view bleeding in real-time 116.  
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Figure 1.7. Life stages of zebrafish 
hpf – hours post fertilization 
At 1 hpf the zebrafish embryo is at the four cell stage. At 25 hpf the body 
axis has formed. At 48 hpf rudimentary organs have formed. The adult male 
zebrafish often appears more streamlined with a golden color. The adult 
females often have a protruding stomach with a bluish color. 
 
Used with permission from Holtzman et al. (2016) 
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Particularly relevant to studying IA development, the cerebral vascular framework of zebrafish is 
conserved among other vertebrates, including humans 121,122. This anatomical resemblance has 
allowed various human cerebrovasculature dysfunctions such as cerebral arteriovenous 
malformations, moyamoya disease, and cerebral amyloid angiopathy to be investigated in a 
zebrafish model 123. Similarities also exist between the cardiovascular system of zebrafish and 
humans. The zebrafish heart consists of two chambers rather than four, but a distinct atrium and 
ventricle are present 116. The average heart rate characteristic of zebrafish is much closer to that 
of humans at 120-180 beats per minute, then the >500 beats per minute typical of mice 117,124,125. 
A closed circulatory framework of arteries and veins is another resemblance between zebrafish 
and humans 116. During the initial days of development, oxygenation of zebrafish embryos is not 
dependent on their circulation. Instead, passive diffusion provides an adequate amount of 
oxygenation for growth 126,127. This becomes particularly advantageous when studying diseases 
that impact cardiovascular development during embryogenesis. Maturing independently of the 
circulation allows zebrafish embryos to survive cardiovascular defects that may be lethal to other 
traditional models 123.  
In addition to the anatomic and physiologic similarities, some homology exists between 
the genomes of zebrafish and humans. The zebrafish genome is highly conserved with that of 
humans, with approximately 70% of human genes having an obvious ortholog within the 
zebrafish genome 128. Although 47% of these human genes have one distinct ortholog in  
zebrafish, this is not true for all genes 128. Specific genes within the zebrafish genome have been 
duplicated, resulting in some cases of multiple zebrafish genes that are co-orthologous to one 
single human gene 129. The duplication of genes within the zebrafish genome is the result of 
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the teleost specific whole genome duplication that occurred at the origin of the teleost lineage 
130–132. It has been suggested that up to 20% of duplicated genes remain in the zebrafish genome, 
and thus, the impact of this whole genome duplication is still relevant 132–134. While the majority 
of human genes do have a clear zebrafish ortholog, there are some in which an ortholog has yet 
to be identified, or no such equivalent exists, thus complicating the investigation of such genes in 
a zebrafish model.  
 
1.3.2 Morpholino Mediated Gene Knockdown 
As the success of zebrafish as functional models of genetic disease has grown, the genetic 
techniques applicable to this organism have also advanced. From the first zebrafish mutant 
generated in 1983, approaches have ranged from forward genetic screening to directed genetic 
engineering using methods such as Clustered, Regularly Interspaced, Short Palindromic Repeats 
(CRISPR/CAS9) mutagenesis and everything in between (Figure 1.8) 135. The use of morpholino 
mediated gene knockdown in zebrafish began when Nasevicius et al. (2000) showed that by 
using antisense, morpholino-mediated oligonucleotides, they could both specifically and 
effectively inhibit translation in zebrafish 136. Initially designed in 1989, the creation of 
morpholino oligonucleotides (MO) was a cost-effective alternative to the expensive nucleic acid 
analogs previously available 137,138. Composed of an uncharged phosphorodiamidate backbone, 
MO ring, and twenty-five bases, these synthetic, antisense RNA  analogs work in vivo to 
effectively bind complementary nucleic acids and hinder gene expression 129,138,139. Splice-
blocking MOs inhibit proper splicing of the primary transcript by binding near the splice site 
while translation-blocking MOs prevent protein synthesis by binding near the start site 129. The 
genetic technique employed by MOs is considered gene knockdown, rather than gene knockout.  
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Figure 1.8. Timeline of significant advancement in zebrafish research 
Used with permission from Varshney et al. (2015) 
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Knockdown is advantageous as gene expression levels can be reduced but not completely 
silenced. The phenotype induced by MO gene knockdown is referred to as a morphant phenotype 
rather than a mutant, which would be the result of CRISPR/Cas9 mutagenesis.   
As the use of MO knockdown in zebrafish grew and additional genetic approaches were 
established, concerns arose regarding the use of MOs as the sole genetic technique for 
investigating genotype to phenotype correlations. A controversial article published by Kok et al. 
(2015) raised questions regarding the reliability of phenotypes observed in morphant zebrafish 
after they found many discrepancies between morphant and mutant phenotypes 140. Although 
other studies have expressed similar concerns, the value of MOs in genetics research should not 
be understated 140–142. Rather than dismiss the use of MOs entirely, many researchers argue that 
adequately controlled MO experiments are the best solution 143,144. From a practical perspective, 
the use of a MO-mediated gene knockdown in a zebrafish model is quite advantageous. MOs are 
easy to use experimentally. Their uncharged phosphorodiamidate backbone makes them 
unappealing to enzymes and thus resistant to degradation. These oligonucleotides are usually 
micro-injected into the yolk of zebrafish embryos anywhere from the 1 to 8 cell stage (Figure 
1.9) 136,145. The whole genome duplication that occurred within the zebrafish genome can make 
the functional investigation of duplicated genes more challenging. However, MOs provide a 
solution to knockdown multiple gene products simultaneously 129. MOs produce genetic 
knockdown rather than genetic knockout. The effectiveness of a MO can be adjusted based on 
the concentration that is used. In circumstances where the expression of a gene is necessary to 
zebrafish survival, the concentration can be titrated to a dose that corresponds with survival 129.  
One specific problem identified early on with MOs use in zebrafish was 15-20% of the 
MOs demonstrated unanticipated off-target effects 146,147. Although the exact mechanism is  
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  Figure 1.9 Embryos during the cleavage period 
(A) 2-cell stage (0.75 h). (B) 4-cell stage (1 h). (C) 8-cell stage (1.25 h). (D) 16-cell stage (1.5 h). 
(E) 32-cell stage (1.75 h). (F) 64-cell stage (2h). Scale bar: 250 μm 
 
Used with permission from Kimmel et al. (1995) 
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unknown, the majority of unanticipated effects are found to be mediated through tumor protein 
p53 (p53) induced apoptosis. To combat the up-regulation of p53 by MOs, the knockdown of 
p53 is recommended. Co-injection with a p53 MO has been found to alleviate the off-target 
effects and thus can be used as a toxicity management tool 144,147. Guidelines also suggest that 
MO phenotypes should be validated by comparing them to a mutant phenotype whenever 
possible. Without comparison to a mutant, MO experiments should take other appropriate 
validation measures. This may include using a second MO that differs in sequence, consistently 
injecting a standard control MO, and incorporating RNA rescue experiments 142. As is the case 
with the majority of experimental procedures, there are advantages and disadvantages associated 
with the use of MOs that should be considered when constructing a study design. 
 
1.3.3 Evaluating Vasculature Dysfunction with Gene Knockdown 
Various studies have used MO-mediated gene knockdown methods to evaluate the role of 
candidate genes on zebrafish vasculature. Not all studies have assessed arterial aneurysm 
development exclusively but provide confidence in the use of this model to evaluate vascular 
dysfunction. Investigations into the role of the Forkhead Box C1 (FOXC1) gene in cerebral small 
vessel disease, a condition with an increased risk of stroke, employed the use of MO-mediated 
gene knockdown in zebrafish 148,149. French et al. (2014) demonstrated that patients with FOXC1 
mutations had increased rates of cerebral hemorrhages, and FOXC1 zebrafish morphants 
produced a hemorrhagic phenotype 148. A paper published by Kiando et al. (2016) used zebrafish 
to investigate fibromuscular dysplasia (FMD) 150. This vascular disease leads to problems in both 
renal and cerebrovascular arteries that can also include aneurysm formation. The MO 
knockdown of Phosphatase and Actin Regulator 1 (PHACTR1), a gene previously associated 
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with FMD, demonstrated subtle vascular impairment in a zebrafish model. In combination with a 
GWAS, this functional analysis provided evidence for Kiando et al. (2016) to report PHACTR1 
as the first identified susceptibility locus of FMD 150.  
 The strong association between ADPKD and IA has been recognized since 4-17% of 
patients with ADPKD eventually develop IA46,151. The contribution of the Survivn gene to 
polycystic kidney disease (PKD) and IA development was investigated by Aboualaiwi et al. 
(2014). Part of their functional analysis involved the MO-mediated gene knockdown of Survivn 
in a zebrafish model in addition to the PKD mice used for functional analysis. The study 
concluded that abnormal expression of Survivn may be contributing to both the cystic kidney 
formation and the vascular aneurysm formation 151.  
 
1.3.4 Modeling Intracranial Aneurysms In Vivo 
 Although various studies have used MO-mediated gene knockdown in zebrafish, few 
studies have assessed arterial aneurysm development exclusively. The studies published by 
Santiago-Sim et al. (2016) and Yang et al. (2018) both employed the use of WES before using 
zebrafish as a functional model for IA 104,105. Yang et al. (2018) used a cohort of 20 Chinese 
individuals with IA and 86 previously unsolved cases of familial IA of Japanese, European, 
American, and French-Canadian ancestry 104. Their sequencing data suggested ARHGEF17 as an 
interesting candidate gene in IA development, and thus, they wanted to investigate further. 
Functional analysis using MO knockdown in a zebrafish model revealed cerebral hemorrhage. 
This evidence allowed them to suggest ARHGEF17 mutations are a risk factor for IA 
development 104. 
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 Santiago-Sim et al. (2016) published a similar study investigating the contribution of 
THSD1 mutations to IA development 105. WES was initially performed on a large family with a 
strong predisposition to IA. A rare missense mutation in THSD1 was ultimately identified as a 
variant of interest, and functional studies were performed in both zebrafish and mouse models. 
The loss of THSD1 expression in the zebrafish with MO-mediated gene knockdown revealed a 
significant cerebrovascular hemorrhage phenotype that was not evident in embryos injected with 
a negative control MO. Similar findings in THSD1 knockdown mice provided further evidence to 
suggest THSD1 mutations may be contributing to IA development 105. Another THSD1 
knockdown in zebrafish was also completed by Haasdijk et al. (2016) using an alternative MO. 
They too demonstrated a significant hemorrhagic phenotype 152. One potential drawback of the 
models expressed by Santiago-Sim et al. (2016) is the lack of aneurysm development observed 
in zebrafish and mouse knockdowns. Instead, a cerebral hemorrhage phenotype is observed 105 . 
They suggested that as is the case with humans, small IAs often go unnoticed. However, it is also 
possible that zebrafish do not develop aneurysms at all and weakening of the vasculature instead 
leads to a hemorrhagic phenotype 105. Therefore, instead of looking for cerebral aneurysm 
formation, a cerebral hemorrhage might be the corresponding phenotype that is observable.  
Other studies have used MO-mediated gene knockdown to evaluate the development of 
thoracic aortic aneurysms and dissections (TAAD), rather than IA. Kuang et al. (2016) 
performed WES on individuals with TAAD from a large family of European descent 153. Variant 
filtering identified Forkhead Box E3 (FOXE3) as a potential candidate gene in TAAD 
development, and thus, functional analysis was performed using MO-mediated gene knockdown 
in embryonic zebrafish. They determined that the aortic arch development was disrupted in 
embryos with FOXE3 knockdown. Furthermore, the study also used mouse embryos to evaluate 
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TAAD development and concluded FOXE3 mutations are likely contributing 153. Preceding the 
publication by Kuang et al. (2016), Guo et al. (2015) published a similar paper assessing the role 
of Methionine Adenosyltransferase 2A (MAT2A) mutations on TAAD development 154. They 
also used WES and functional studies, which demonstrated that MAT2A-deficient zebrafish 
experienced significant cerebrovasculature dysfunction. Thus suggesting MAT2A mutations may 
predispose to TAAD development 154. The co-morbidity that exists between IA and other arterial 
aneurysms, and the similarity of their vascular pathology, provides confidence that studies of 
TAAD are also employing zebrafish models. The detailed methodology outlined does differ 
within each study, and therefore it is important to note that significant variations are contributing 
to their respective results. However, the current literature helps speak to the appropriateness of 
zebrafish as a functional model.  
 
1.4 Newfoundland and Labrador Population 
The unique genetic architecture of the Newfoundland and Labrador (NL) population has 
made it an appealing cohort in genetic research for many years. This 405,212 km2 island is the 
most easterly province in Canada and is home to approximately 525,000 people 155. Immigration 
to NL from Europe, which was already inhabited by Indigenous People, predominately took 
place between the eighteenth and nineteenth centuries 156. The majority of individuals originated 
from southwestern England and southeastern Ireland, and were drawn to fishing opportunities off 
the NL coast 156. Isolated communities began to develop along the shoreline of the province, 
many of which still exist today. The remote settlement of many outport communities, some of 
which are only accessible by boat, has caused persistent geographic isolation 157. The small 
founder population and minimal immigration, in combination with the geographic isolation, has 
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resulted in a population with an increased inbreeding coefficient and reduced genetic 
heterozygosity 157–159.  
The NL population has an exceptionally high incidence of various monogenic and 
complex diseases 157. Only surpassed by Finland, the NL population has the second-highest 
incidence of type 1 diabetes mellitus (T1DM) on the planet and the prevalence of colorectal 
cancer in the NL population is the highest in Canada 160. In addition to T1DM and colorectal 
cancer, genetic studies of Bardet-Biedl syndrome, hemophilia A, multiple endocrine neoplasia 
type 1, psoriatic arthritis, and cardiomyopathies have all been facilitated in the province 161–165. 
Although these conditions contribute significantly to the burden of disease, they have also 
highlighted this population as an appropriate and successful cohort to use for various genetic 
disease investigations. Within the NL population, numerous families have a strong genetic 
predisposition to IA and thus this cohort became the focus of this thesis 157,166.  
 
1.5 Hypotheses and Objectives 
I hypothesize that highly penetrant pathogenic variants predispose to IA in families from NL. 
Furthermore, the genetic knockdown of candidate gene(s) in zebrafish will recapitulate a 
hemorrhagic phenotype.  
The goal of this project is to identify any pathogenic variants potentially relevant to the 
development of IA in families from NL. The first objective is to prioritize the genetic variants 
generated from the exomes of study participants affected with IA. Secondly, I will use Sanger 
sequencing to validate these genetic loci and assess the familial segregation. The final objective 
is to functionally analyze candidate variants that are identified as potentially pathogenic using 
MO-induced gene knockdown in a zebrafish model. 
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1.6 Relevance  
Bleeding within the subarachnoid space results in devastating clinical outcomes with 
substantial morbidity and mortality. In 30% of SAHs, the outcomes are fatal, and an additional 
30% require nursing care as they are unable to live independently 167. As the most common non-
traumatic cause of SAH is ruptured IA, improving the management of IA is of utmost 
importance. Identifying genetic variants responsible for familial IA development could lead to 
new diagnostic techniques and thus reduce the amount of imaging required for screening.  A 
better understanding of IA pathogenesis could also assist in detecting a potential novel 
therapeutic target. These could eventually lead to advancements in current treatment options and 
the development of prophylactic strategies.  
  
 46 
2. Materials & Methods 
2.1 Study Participants 
Before my project, significant work was already completed, focusing specifically on two 
study families, R1352 and R1256 168. These two families provided an ideal cohort for initial 
investigations. There was a particularly strong incidence of IA, and many of the unaffected 
family members were consenting study participants. With a more focused study already 
completed, and such an extensive cohort of families available, I expanded my project to focus on 
13 of our multiplex families from across NL. This included 46 affected individuals and 308 of 
their unaffected relatives (Table 2.2). The average age of initial diagnosis for these affected 
individuals was 50.5 years of age, and 80% of them were females.  
The recruitment of study participants affected with IA from across NL occurred before 
the beginning of this project and has been described previously 168. Recruitment of individuals 
began as a collaborative effort between neurosurgeon Dr. Falah Maroun and medical geneticist 
Dr. Bridget Fernandez (Figure 2.1). Potential participants were referred to the study by 
neurologists and neurosurgeons across Eastern Health. Consenting patients were considered 
“affected” if an IA was identified via computed tomography (CT) scan or magnetic resonance 
imaging (MRI). Subsequently, a three-generation pedigree was collected from all affected 
participants, and any consenting family members were also recruited to the study.  
 Further classification of participants was then necessary to identify whether an 
individual’s IA was familial, sporadic, or equivocal in origin. Familial IA was defined as an 
affected individual with one or more first or second-degree relatives with a known IA. 
Conversely, sporadic IA was defined as an individual with no known family history of IA. Any 
undetermined case, in which an IA is not definitively familial or sporadic, was considered  
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equivocal IA. To date, a total of 53 families have been recruited to the study, encompassing 92 
affected individuals and 396 unaffected relatives. An additional 33 sporadic and five equivocal 
IA cases were also participants in the study.  
 Clinical data from all affected individuals was collected, including: their date of birth, 
age of initial diagnosis, number of IAs, size and location of IA, whether a SAH occurred and if 
surgical intervention was required. Details of the surgical technique performed (clipping or 
coiling), as well as any surgical complications, were also recorded. Finally, a detailed medical 
history was collected from all affected study participants, specifically inquiring about risk factors 
known to lead to IA development such as hypertension, smoking, and DM (Table 2.1).   
 
2.2 Whole Exome Sequencing 
 The first iteration of WES began in 2015 when 23 exomes, representing six families, 
were sequenced. In 2016, 19 more exomes, representing seven additional families were also sent 
for sequencing (Table 2.1). The exomes were sequenced at The Centre for Applied Genomics 
(TCAG) at The Hospital for Sick Children in Toronto, Ontario. An Illumina HiSeq2500 platform 
was used for sequencing. All DNA samples were submitted to TCAG in 70 ul aliquots at 100 
ng/ul with an optical density (OD260/280) ratio between 1.8 and 2.0 to meet sample purity 
standards. With a previous study already completed, the exome data required for this project was 
available. The following information regarding the WES platform outlines steps completed by 
TCAG and has been adapted from the material provided by TCAG with additional information 




2.2.1 Library Preparation & Cluster Generation 
 Samples were prepared by first undergoing ultrasonic vibration that produces random 
fragmentation of the DNA. Adapters were ligated to both the 5’ and 3’ ends of the DNA 
fragments, which can then be polymerase chain reaction (PCR) amplified, followed by 
purification with gel electrophoresis 170. Oligos complementary to the ligated adapters are bound 
to a flowcell where they can capture the DNA fragments. Through bridge amplification, distinct 
clonal clusters are then generated from each fragment 170.  
 
2.2.2 Sequencing 
 The HiSeq2500 uses Sequencing by Synthesis technology that utilizes reversible 
terminator chemistry for base-by-base sequencing 171. During each sequencing cycle, four 
reversible terminators are present (A, C, T, G), all of which are fluorescently labeled. After each 
cycle, the deoxyribonucleotide triphosphate (dNTP) that was incorporated can be identified by 
the emission wavelength. This technology allows for a natural selection of the base incorporated 
into the DNA template strand, which is understood to reduce error rates and incorporation bias 
172. 
 
2.2.3 Sequence Alignment & Quality Control  
 Once the base calls have been identified, the sequencing reads were aligned to the 
genome reference consortium human build 37 (hg19) reference genome using the Burrows-
Wheeler Alignment Tool version 0.5.9 173. This tool can align short sequence reads against a 
large reference sequence while adapting to any disruptions and discrepancies between the two 
sequences 173.  
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Table 2.1. Clinical Data for all affected study participantsv 









Z991* R1262 F 46 1 No surgery N N/A 
Z1037* R1262 F 56 1 Clipping N N/A 
Z1133* R1381 F 56 2 Clipping Y N/A 
Z1137* R1381 M 52 1 No surgery Y Hypertension, Depression, Anxiety 
Z1369* R1381 F 64 1 No surgery N N/A 
Z994* R1265 F 50 1 Coiling Y N/A 
Z995* R1265 M 63 1 No surgery N N/A 




Z1150* R1385 F 31 1 No surgery N N/A 
Z1007* R1276 M 67 1 Clipping N N/A 
Z1015* R1276 F 59 1 Clipping N N/A 
Z1017* R1276 M 72 1 Clipping Y AAA, Hypertension 
Z1008* R1277 M 45 1 No surgery N N/A 
Z1304* R1277 M 26 1 No surgery N N/A 
Z1305* R1277 M 54 1 No surgery N Hypertension, Reflux 
Z1353* R1277 F 51 2 Coiling Y Hypertension, Smoker 
 




Z1354* R1277 M 50 1 No surgery N N/A 
Z1355* R1277 F 54 2 Coiling Y Hypertension 
Z984 R1888 F 68 2 No surgery N Hypertension, Breast Cancer 
Z1043* R1888 F 53 1 Clipping N Ex-smoker 
Z1102* R1888 F 45 1 No surgery N 
Smoker, 
Hypercholesterolemia
, Crohn’s Disease 
Z1427* R1888 M 69 1 No surgery N Asthma 
Z1054* R1357 F 46 3 Clipping N Hypertension, Smoker, Reflux 
Z1069* R1357 F 34 2 Clipping Y Smoker, Hypothyroidism 
Z1297 R1357 F 37 1 No surgery N Smoker, Hyperlipidemia 
Z1365* R1357 F 57 1 No surgery N Hypertension, Pulmonary Fibrosis 
Z1366* R1357 F 45 1 Clipping N N/A 
Z1159 R1400 F 20 1 No surgery N Migraines 
Z1360* R1400 F 36 1 No surgery N GERD 
Z1364* R1400 F 47 2 Clipping Y Cognitive Impairment 





Z1317* R1383 F 31 1 No surgery N Migraines 
Z1395* R1893 F 57 3 Coiling Y Smoker, GERD, COPD 














Z1013 R1256 F 29 2 Clipping Y N/A 




Z1405 R1256 F 51 4 Coiling N 
Ex-smoker, 
Hypercholesterolemia
, Asthma, GERD, 
Fibromyalgia 
Z1406 R1256 F 47 1 Clipping Y Hypertension, Hyperlipidemia 
Z1441 R1256 M 48 1 No surgery N Hypertension, Smoker 








Z1471* R1256 F 50 3 No surgery N Smoker 




, DM, Osteoarthritis, 
Burkitt’s Lymphoma, 
Diverticulosis 











Table 2.2. Classification of study participants within each familial cohort  
Family Number of Affected DNA Available Unaffected Study Participants 
R1256 12 11 51 
R1262 4 2 0 
R1265 2 2 6 
R1276 3 3 55 
R1277 6 6 7 
R1357 5 5 41 
R1381 3 3 8 
R1383 3 2 14 
R1385 3 2 1 
R1400 5 3 62 
R1888 6 4 23 
R1893 3 1 14 
R2409 2 2 25 












 Even with the advancements in WES, there are possible sources of error associated with 
using this technology. During the library preparation step, ideally only one PCR copy of each 
original DNA fragment would hybridize to the flowcell. However, this is not always the case, 
and occasionally, PCR duplicates arise. Any erroneous mutations introduced within these 
duplicates will then occur more often than appropriate, causing amplification induced errors 174. 
Therefore, duplicate reads were removed via Picard version 1.79 175. Additionally, the presence 
of indels within an exome often result in intervals of misalignment and thus inaccurate variant 
calls.  The Genome Analysis Toolkit (GATK) version 1.1-28, indel realigner tool was used to 
identify these suspicious intervals and realign the reads 176,177. Systemic technical errors that 
result from the Illumina instrument itself were also addressed by detecting technical errors using 
GATK and adjusting the base quality scores accordingly 178. 
 
2.2.4 Variant Calling 
 After the alignment of sequenced reads to the reference genome, and the quality control 
steps were performed, TCAG also provided data analysis. Variants were identified by comparing 
the sequenced exomes to the reference genome; this included both SNVs and indels. Variant 
calling was implemented via GATK, which utilizes the Bayesian genotype likelihood model to 
call variants on a per locus basis 178.  
Initial variant filters were applied by bioinformatics at TCAG to ensure variant calls were 
actual genetic variations and not sequencing artifacts. All identified SNVs were subject to variant 
quality score recalibrations (VQSR) and indels overlapping repeat masked regions were 
discarded 176. Variant calls were also hard-filtered based on Quality Depth score, Rank Sum Test, 
and Strand Bias (SB). The higher the read depth, the more confidence there is in a particular base 
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call. However, each read contributes to the quality score. Thus regions of the exome that have 
more in-depth coverage can have artificially inflated quality scores 176. To account for this, the 
variant confidence by depth was normalized to less than 10. A filter of less than -20.0 on the 
Rank Sum test was also applied. Sequences tend to make the most errors at the ends of reads, and 
therefore seeing an allele only at the end is indicative of a false call. The Rank Sum test 
evaluates how well the reference allele and the alternative alleles are supported 177. Finally, 
sequencing occasionally favors one DNA strand over the other, which can result in an 
inappropriate amount of evidence in support of one allele 179. Therefore, a filter of greater than 
0.01 SB was also applied. 
  
2.2.5 Annotation 
 Prior to beginning variant filtering, variant annotation pipelines helped characterize the 
large amount of genetic information. ANNOVAR was the program used by TCAG to annotate 
the genetic variants called by GATK and predict their functionalities. There are three significant 
pipelines used by ANNOVAR. The gene-based annotation identifies any variant affiliation with 
known genes and their potential functional impact 180. This provided details such as the location 
of the variant, the amino acid change, and the functional role of the variant (nonsynonymous, 
frameshift, etc.) 180. The region-based annotation identifies variants in specific genomic regions, 
for example recognizing if a variant resides in a conserved region of the genome. Furthermore, 
the filter-based annotation provides details on the variant via information retrieved from several 
external databases 180. The details provided from the filter-based annotation include whether the 
variant was previously reported in the Single Nucleotide Polymorphism database (dbSNP), 
ClinVar, or Online Mendelian Inheritance in Man (OMIM) databases.  Allele frequencies were 
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also provided from the 1000 Genome Project, National Heart Blood and Lung Institute (NHBLI), 
Exome Aggregation Consortium (ExAC) and Complete Genomics (CG). In addition, mutation 
prediction algorithm scores such as sorting intolerant from tolerant (SIFT), Polyphen and 
Combined Annotation Dependent Depletion (CADD) were included to provide predictions on 
the pathogenicity the amino acid change will have on the protein.  
 TCAG provided the sequencing data for each of the exomes in annotated variant tables, 
grouped by family. Each row corresponded to an identified variant within the family and each 
column corresponded to a specific annotation field. The files were easily transferred to Microsoft 
Excel, where each table could then be used for variant filtering. 
  
2.3 Variant Filtering 
 A variant filtering strategy was developed and implemented that could assist in 
prioritizing the large number of variants generated from WES while excluding those unlikely to 
be pathogenic (Figure 2.2). Amy Powell, who completed the previous IA project in the Woods 
lab focusing on two specific families, significantly contributed to the study design and 
development of the variant filtering strategy used in this project. The approach used considered 
our current knowledge of IA, previous work in the Woods Lab, filtering strategies of previous 
WES studies, and suggestions provided by TCAG for variant prioritization.  
 
2.3.1 Preliminary Variant Filtering 
 The initial filtering steps were suggested by TCAG and were implemented to provide 
quality control, eliminating sequencing artifacts, and instead identifying only true genetic 
variants. Any variant with a read depth less than 10 from all exomes within a single family was 
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excluded. Furthermore, the GATK primary filter that is based on the VQSR provides variants 
with a “PASS” value if they are more likely to be true genetic variants. Thus, only variants with 
a PASS value were included for further filtering.  
Although the role of synonymous variants in heritable disease is now better understood, 
synonymous variants were excluded at this point to implement a more stringent filtering strategy, 
which focused on potentially more damaging variants 181,182. Recent studies have also 
demonstrated the importance of noncoding regions of the genome in disease development 183. 
However, excluding noncoding variants was another filtering step implemented to reduce the 
large number of genetic variants prioritized. Finally, any variants with a minor allele frequency 
greater than 1% in ExAC, NHLBI, 1000 Genomes and CG Datasets were also excluded as IA is 
a relatively rare disorder. 
The late onset of IA, combined with the generally asymptomatic development, makes it 
difficult to definitively classify an individual as truly unaffected. Small IAs can sometimes 
resolve or rupture unnoticed, and the brain takes care of the hemorrhagic blood products via 
normal blood degradation pathways 184,185. Therefore, even a seemingly negative CT or MRI can 
inaccurately classify an individual as unaffected. These challenges have made it acceptable to 
include only affected individuals in WES when studying IA. Thus, variants not shared by all 
affected individuals were excluded. In two particular families, R1381 and R1277, there are 
family members who have AAAs but no IAs (Z1371 and Z1304). While this did not classify 
them as affected participants within the study, there has been sufficient research investigating the 
link between AAA and IA 186–188. For this reason, these two families were filtered in two 
different ways, initially considering Z1371 and Z1304 as affected individuals and then excluding 
them as affected individuals.  
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Figure 2.2. Variant filtering strategy 
The genome analysis toolkit (GATK) – software version 1.1-28, Minor allele frequency (MAF), 
Exome Aggregation Consortium (ExAC), National Heart Blood and Lung Institute (NHLBI), 
Sorting intolerant from tolerant (SIFT), MutationAssessor (MA), MutationTaster (MT), PhyloP 
placental mammals (PhyloPMam), PhyloP 100 Vertebrates (PhyloPVert100), Combined Annotation 
Dependent Depletion (CADD) 
 
Exclusion of Variants: 
- Read depth <10x 
- Without a PASS in GATK 
- Noncoding and synonymous 
- MAF >1% 
 
Inclusion of Variants: 
- Predicted deleterious in 4/7 bioinformatics tools 
MAF reported in: 
- ExAC 
- NHLBI 
- 1000 Genomes 







Prioritization of Variants: 
- Shared in multiple NL families 
- In previously reported candidate IA genes 
Candidate IA genes published by: 
- Farlow et al. (2015) 
- Yan et al. (2015) 







 Further filtering of variants was still required to help prioritize variants for investigation. 
Different types of genetic variations have variable impacts on a gene. For example, frameshift 
and stopgain mutations usually cause major disruptions in a gene, whereas nonsynonymous 
SNVs are thought to have a more moderate impact. For this study, only nonsynonymous SNVs 
that were predicted deleterious by 4/7 bioinformatic tools were considered further (Table 2.3). 
The bioinformatics tools used included: MutationAssessor (MA), MutationTaster (MT), SIFT, 
Polyphen2, PhyloP, and CADD. MA and MT use functional prediction algorithms to provide 
predictions of the pathogenicity an amino acid change will have on a protein 189–191. Polyphen2 
and SIFT both use scales from 0.1-1.0, with opposite implications. A low Polyphen2 score 
indicates an amino acid substitution that is likely tolerated, whereas a low SIFT score indicates a 
deleterious amino acid substitution. PhyloP scores for placental mammals and 100 vertebrates 
were also considered which measure the evolutionary conservation of an amino acid change 192. 
Finally, CADD scores, a tool that integrates various annotations into a single ensemble score, 












Table 2.3. Bioinformatics predictive criteria 
Predictive Criteriavi Score 
SIFT <= 0.05 
Polyphen2 >= 0.90 
MA >= 1.90 
MT >= 0.5 
PhylopMam >= 2.30 
PhylopVert100 >= 4.0 




vi All nonsynonymous single nucleotide variants (nsSNV) that did not meet at least 4/7 predictive criteria were 
excluded from further consideration 
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2.4 Variant Prioritization 
2.4.1 Published IA Candidate Genes    
 Once the variant filtering strategy had been designed and implemented, further 
prioritization of the remaining variants was required. All variant prioritization strategies 
described were weighted equally. I searched my list for variants within published IA candidate 
genes. As mentioned in the introduction, previous studies have also used WES to evaluate the 
genetic contribution that is leading to IA formation. Farlow et al. (2015) performed WES of 45 
individuals, representing seven multiplex families that were recruited as part of the FIA study 100. 
With the use of this cohort, Farlow et al. (2015) published 68 candidate variants in 68 genes that 
segregated with IA in at least one family. Another study by Yan et al. (2015) also performed 
WES of 42 individuals, representing 12 families of Japanese ancestry 101. They ultimately 
published 78 candidate IA variants. I compared both of these IA candidate gene lists with my 
remaining variants and any variants found in genes that were highlighted in both lists were 
prioritized for further consideration.  
 
2.4.2 Variants Shared in Multiple NL Families 
 The reduced genetic heterogeneity of the NL population made it plausible to assume the 
same genetic variant, or different variants within the same gene, could be contributing to IA 
development in more than one of our study families. Therefore, any variant that was present in 
all affected family members, in two or more families was prioritized for further analysis. In 
addition, different variants in the same gene, present in multiple families, were also prioritized 
for further consideration. 
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2.5 Validation and Testing Familial Segregation 
 To validate the prioritized variants and eliminate any false positives variants introduced 
by WES, Sanger sequencing was completed on all available affected individuals from each 
family (Table 2.1). Any variants that did not segregate with all affected individuals within a 
family were not prioritized. Once the variants were validated, any available unaffected 
individuals from each respective family were also Sanger sequenced. Locating a variant in a 
seemingly unaffected relative did not exclude the variant from further investigations as the late 
onset of IA, and incomplete penetrance, makes it difficult to determine if an individual is an 
unaffected carrier, or not. Therefore, variants were analyzed individually and needed to be absent 
from a large percentage of unaffected individuals. The sequencing of both affected and 
unaffected individuals would provide a more thorough representation of how each variant 
segregated within a family.  
 
2.5.1 Population Controls 
 After segregation analysis, 100 NL population controls were Sanger sequenced for any 
variants that emerged as top candidates to proceed with for functional analysis. By sequencing 
population controls, the prevalence of these variants in the NL population could be examined, as 
the reported MAF may not be exemplified in a relatively homogenous population such as this. 
The controls were available from the Newfoundland Colorectal Cancer Registry Project 
(NFCCR) and consisted of participants that had no known personal or family history of cancer. 





2.6 Sanger Sequencing 
 The Sanger sequencing protocols described here are standard methods used in the Woods 
lab and were used for all sequencing reactions.  
 
2.6.1 DNA Extraction from Whole Blood 
 As WES data was already available at the beginning of this project, most DNA 
extractions were previously performed. However, not all study participants were analyzed in 
previous projects, and the poor quality of some previously analyzed samples required more DNA 
extractions to be completed. The extraction of DNA from whole blood was completed in a 
Laminar Flow Biosafety Containment Cabinet, following the protocol from the Wizard® 
Genomic DNA Purification Kit (Promega). The first step in DNA extraction requires the lysis of 
whole white blood cells and their nuclei to access the DNA. To begin, 30 ml of cell lysis solution 
was added to a 50 ml sterile centrifuge tube. The tube of whole blood was gently rocked until 
mixed thoroughly and then 10 ml was transferred to the 50 ml sterile centrifuge tube containing 
the cell lysis solution. The tube was then inverted six times to mix. This mixture was then 
incubated at room temperature for 10 minutes, inverting six times halfway through incubation to 
lyse the red blood cells. 
 After the incubation, the mixture was centrifuged at 2000 x g for 10 minutes in the 
SorvallTM LegendTM T+ Centrifuge (Thermo Fisher Scientific) and the supernatant was discarded 
without disturbing the pellet at the bottom of the tube. The tube was then vortexed to re-suspend 
the white blood cells and 10 ml of nuclei lysis solution was added prior to the tube being 
vortexed again. In order to remove any cellular proteins and isolate the DNA, 3.3 ml of protein 
precipitation solution was added. The solution was mixed using a motorized pipette and the tube 
 64 
was then centrifuged for 10 minutes at 2000 x g.  
 The final step in DNA extraction aimed to concentrate the DNA and remove any 
remaining precipitation solution. The supernatant was transferred to a fresh 50 ml sterile 
centrifuge tube containing 10 ml of isopropanol at room temperature. The solution was gently 
mixed by inversion until the white, thread-like strands of DNA formed a visible mass and was 
then centrifuged at 2000 x g for two minutes. The supernatant was decanted and 10 ml of 70% 
ethanol was added to the DNA. The tube was gently inverted several times to wash the DNA 
pellet and the sides of the centrifuge tube. The tube was again centrifuged at 2000 x g for two 
minutes. The remaining ethanol was carefully aspirated, and the pellet was left to air-dry 
overnight. Finally, the DNA was dissolved in 400 ul of rehydration buffer and left to incubate at 
room temperature overnight. The DNA sample could then be mixed, and the concentration could 
be quantified.  
 
2.6.2 Polymerase Chain Reaction 
 The PCR completed in the first step of Sanger sequencing allows amplification of the 
DNA sequence of interest, generating millions of copies. Initially, all primer sets were optimized 
using a standard temperature gradient to identify their ideal annealing temperature. Specific 
primer sequences and optimal annealing temperatures can be found in Appendix A. The 
InvitrogenTM PlatinumTM Taq DNA Polymerase Kit was used for all PCR (Thermo Fisher 
Scientific).  
 All DNA samples were first diluted to standard 100 ng/ul aliquots. A PCR master mix 
was made containing 10x PCR buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl) (1.5 ul), 100 
ng/ul dNTPs (0.375 ul), forward primer at 10 mM (0.5 ul), reverse primer at 10 mM (0.5 ul), 50 
 65 
mM MgCl2 (0.75 ul), Taq DNA polymerase at 5 U/ul (0.15 ul) and 10.225 ul of distilled H2O.  
The master mix was made in a 1.5 ml microcentrifuge tube and then 14 ul of mix was 
individually transferred to each well of a 96 well PCR reaction plate where 1 ul of genomic DNA 
at 100 ng/ul was added as well. A negative control sample was included in each PCR; containing 
the PCR master mix without any genomic DNA to ensure there was no contamination. The PCR 
plate was capped, vortexed and centrifuged for 1 minute at 300 rpms before being placed into the 
Verti 96-well Thermal Cycler (Applied Biosystems). Specific thermal cycler protocols for each 
respective primer set can be found in Appendix B.  
 Agarose gel electrophoresis was used to view the PCR products, ensuring each sample 
was amplified and the primers were specific to the DNA sequence of interest. The agarose gel 
was prepared in an Erlenmeyer flask with 50 ml of 1x Tris-Acetate-EDTA (TAE) buffer and 1 g 
of UltraPure agarose (Thermo Fisher Scientific). This mixture was microwaved for 75 seconds 
before 3.75 ul of SYBR safe DNA gel stain (Thermo Fisher Scientific) was added. The mixture 
was then poured into a cassette with a 16-well, 1.5 mm comb and was left to allow the gel to set. 
After 20 minutes the comb was removed, and each well was loaded with 3.5 ul loading dye and 3 
ul PCR product. The first well was reserved for 3.5 ul of loading dye and 1 ul of 100 bp DNA 
ladder. The gel was then loaded into the electrophoresis chamber and ran at 120 V for 25 
minutes. The gel was then viewed via an AlphaImager®EP (SelectScience) under trans 
ultraviolet light to confirm DNA amplification. 
  
2.6.3 EXOSAP 
 After ensuring the DNA fragments were amplified, an exonuclease shrimp alkaline 
phosphatase (exosap) step was performed prior to beginning the cycle sequencing reactions. This 
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step acts to clean up the PCR products as exonuclease removes any excess primers, while the 
shrimp alkaline phosphatase removes any unincorporated dNTPs. An exosap master mix was 
made with 20 U/ul exonuclease (0.25 uL) (Thermo Fisher Scientific), shrimp alkaline 
phosphatase (0.5 ul) (Thermo Fisher Scientific) and 4.25 ul of distilled H2O. The mixture was 
made in a 1.5 ul microcentrifuge tube, and 5 ul was individually transferred to each well of a 96-
well PCR reaction plate along with 5 ul of PCR product. Once each well contained 5 ul exosap 
mix with 5ul of PCR product, the plate was capped, vortexed and centrifuged at 300 rpm for 1 
minute. The plate was then placed into the Verti 96-well Thermal Cycler (Applied Biosystems). 
Specific thermal cycler protocols can be found in Appendix B. 
 
2.6.4 Cycle Sequencing Reactions 
 After exosap cleanup of the PCR products, cycle sequencing reactions were setup on ice 
using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific). An 
individual master mix was made for both the forward and reverse primers in each set. The master 
mix contained BigDye® Terminator v3.1 Ready Reaction Mix (0.5 ul), 5X Sequencing Buffer 
(2.0 ul), respective primer at 10 mM (0.67 ul) and 14.83 ul of distilled H2O. Each well of a 96-
well PCR reaction plate was then individually loaded with 18 ul of master mix and 4 ul of exosap 
product. The plate was then capped, vortexed and centrifuged at 300 rpm for 1 minute before 
being placed on the Verti 96-well Thermal Cycler (Applied Biosystems). Specific thermal cycler 
protocols can be found in Appendix B.  
 
2.6.5 Ethanol Precipitation 
 Prior to loading the cycle sequencing reactions onto the sequencer, a series of ethanol 
precipitation steps were performed to precipitate the DNA. Initially, 95% ethanol (65 ul) was 
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added to each well. Subsequently, 125 mM EDTA (5 ul) was added to remove any 
unincorporated dye terminators that could obscure the sequencing data and help stabilize the 
extension products throughout the precipitation. The plate was then capped, vortexed and 
centrifuged at 300 rpm for 1 minute. In order to allow time for precipitation, the plate was then 
left undisturbed in a drawer overnight, or in the fridge for 30 minutes to 1 hour.  
 The samples were then removed from the drawer and centrifuged for 30 minutes at 3000 
x g. The caps were removed, and the plate was blotted onto paper towel to remove the ethanol 
without disturbing the DNA pellet. To ensure the removal of any remaining ethanol, the plate 
was inverted on paper towel and centrifuged at 300 rpm for 1 minute. Thereafter, 70% ethanol 
(150 ul) was added to each well and the plate was capped, vortexed and centrifuged for 15 
minutes at 3000 x g. The caps were again removed, and the plate was blotted onto paper towel to 
remove the ethanol without disturbing the DNA pellet. The plate was inverted on paper towel 
and centrifuged at 300 rpm for 1 minute to remove any excess ethanol. To ensure that all of the 
ethanol had now been removed, the plate was left to dry in a drawer for 30 minutes with the caps 
removed.  
 Once it was ensured the plate had completely dried, the samples were re-suspended with 
the addition of 10 ul of highly deionized formamide to each well. The plate was capped, vortexed 
and centrifuged at 300 rpm for 1 minute before being placed on the Verti 96-well Thermal 
Cycler for denaturing (Applied Biosystems). Specific thermal cycler protocols can be found in 
Appendix B. Once the samples are denatured, the caps are removed, and a 96-well silicon septa 
matt was placed on top of the plate. 
 The cycle sequencing reactions were then ready for sequencing and the plate was placed 
onto the ABI3130 Genetic Analyzer (Applied Biosystems). Once the sequencing was completed, 
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the data collected was removed from the sequencer and visualized via the sequencing analysis 
software Sequencher 5.0 (Gene Codes Corporation). This analysis software shows individual 
bases of the DNA segment and provides the corresponding sequence chromatograms. A 
reference sequence was then aligned to the DNA sequence of interest and any inconsistencies 
could be identified.  
 
2.7 Functional Analysis in a Danio rerio Model 
2.7.1 Candidate Gene Prioritization 
 In order to determine which variants should be prioritized for further functional analysis 
in a zebrafish model, a segregation analysis was performed for each candidate variant. To be 
prioritized, variants needed to segregate with all affected individuals within a family and they 
also needed to be absent from a high percentage of unaffected individuals within the family.  
 Up until this point, an unbiased filtering approach was used that did not employ any 
assumptions about biological processes or pathways. Following segregation analysis, the 
functionality of each candidate gene was investigated further. The web-based program, Varelect, 
was used to identify phenotype relationships between candidate genes and IA formation 194. The 
program uses information collected from GeneCards and its affiliated databases to draw 
connections between the genes and phenotype keywords entered by the user. The query terms 
used to search for IA associations were “intracranial aneurysm”, “aneurysm”, “intracranial”, 
“subarachnoid hemorrhage”, “blood vessel” and “extracellular matrix”. Varelect then rates the 
genes as directly or indirectly related to the phenotype keywords and provides information on the 
relationships drawn 194.  
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 To further aid in candidate gene prioritization, a review of the functional work already 
completed in model organisms was performed. By using both Mouse Genome Informatics and 
the Zebrafish Information Network candidate genes could be searched, and any evidence 
obtained from model organisms could be reviewed 195,196. Searching a particular gene in either 
database provides curated reference lists for any research related to these genes in the respective 
model organism. While the evidence obtained from these model organisms was not used as a 
definitive filter of any genes, the information was used to review what functional work, if any, 
had already been completed on a particular gene. 
  
2.7.2 Morpholino Mediated Gene Knockdown in Zebrafish 
 The functional work completed for this project was done in collaboration with Dr. Curtis 
French at Memorial University in the Faculty of Medicine. The MO-mediated gene knockdown 
protocols described here are standard protocols used in the French Lab and were used for all MO 
injections throughout the project. Prior to beginning injections, 300 nmol MOs were diluted to 
standard 3 ng/nl aliquots and heated for 10 minutes in a 65°C water bath. Both splice-blocking 
and translation-blocking MOs were used, and specific oligonucleotide sequences can be found in 
Table 2.4. There was no MO previously published for METTL20 and thus a MO was designed 
via GeneTools software (Gene Tools, LLC).  
Initially, each MO was injected at two different dosages into live zebrafish embryos at 
the one cell-stage. The initial injection was approximately a 3 ng dose, followed by a higher dose 
at approximately 9 ng. An equivalent dose of standard control MO was also included at each 
round of injections to ensure any observed phenotype was not the result of off target effects. The 
standard control MO was purchased from GeneTools (Gene Tools, LLC) and should have very  
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MO MO Sequence Published 
HAL hal splice blocking GCCATTATAAAGGATACAGATGCGA 
Han et al. 
(2016)197 
METTL20 mettl20 translation blocking ATCGATAATTTTGTCCTGTAACCGG N/A 
































little biologic activity with no specific target in the zebrafish genome. Injections were completed 
under a Nikon SMZ18 stereomicroscope, immediately following embryo collection. Following 
injections, embryos were separated based on dosage, and stored in petri dishes with 1X embryo  
media, incubated at 28.5°C. Embryo media was made in a 1L bottle containing 50 ml of 20X 
embryo media, 946 ml reverse osmosis (RO) H2O, and 4 ml of 500X sodium bicarbonate. The 
embryo media was made fresh each week and stored at room temperature. The recipe for the 
20X embryo media can be found in Appendix C. 
At 24 hours post fertilization, embryos were screened using a stereomicroscope to 
remove any deceased or unfertilized embryos. The embryo media in each petri dish was also 
removed and replaced with 1-phenyl 2-thiourea (PTU) media mix. PTU mix was prepared in a 1 
L glass bottle containing 500 ml of embryo media along with 20 mg of PTU. The mixture was 
placed on a stir plate and left to mix overnight. PTU media prevents embryo pigmentation, thus 
the embryos continue to develop transparently, and a hemorrhage phenotype can be readily 
identified 200. At 30 hours post fertilization, embryos were removed from their chorions and 
subsequently at 48 hours post fertilization, embryos were imaged. Embryos were again imaged at 
72 hours post fertilization to determine if any additional hemorrhages were observable.  
The MOs that produced a significant dose dependent hemorrhagic phenotype were then 
co-injected with p53 at a higher dose of MO. The addition of p53 allows an increase in the 
dosage of a MO without causing unwanted off target effects 147,201. An equivalent dose of p53 
MO was also included at each round of injections to ensure any observed phenotype was the 




2.7.3 Rescue Experiment 
 To validate the specificity of the hemorrhagic phenotype characteristic of hal morphants, 
a rescue experiment was performed. Prior to beginning the rescue experiment, mutant and 
wildtype human HAL RNA was synthesized from open reading frame (ORF) expression clones 
generated by GeneCopoeia (GeneCopoeia, Inc). The ORF cell free expression clones contain a 
wheat germ cell free vector backbone and T7 promotor (Figure 2.3).  
 
2.7.3.1 Transforming Chemically Competent E.coli Cells 
 LB agar plates were made by adding 10 g LB agar powder to 250 ml of RO H2O in a 500 
ml flask. The mixture was autoclaved and then spun on a stir plate until cool enough to handle  
(approximately 20 minutes), being careful not to allow solidification. Ampicillin antibiotic was 
added, the solution was transferred to petri dishes using a sterile technique, and plates were left 
at room temperature overnight.  
E.coli cells were thawed on ice, and 33 ul of cells were transferred into a 1.7 ml 
centrifuge tube for each transformation. Three solutions were made, one for each of wildtype 
DNA, mutant DNA, and a control. Without mixing, 1 ul of DNA (H20 in control) was added 
directly to the cells and left on ice for 20-30 minutes. The solution was then heat shocked for 30  
seconds at 42°C, then placed on ice for another two minutes. Following the ice, 200 ul of SOC 
media was added to each solution, and tubes were shaken at 37°C for 1 hour. The tubes were  
removed from the each solution, and tubes were shaken at 37°C for 1 hour. The tubes were 
removed from the shaker and spun for three minutes at 3,000 rpm, allowing a cell pellet to form. 
After removing 175 ul of media, the cells were resuspended by gently pipetting the remaining 50 
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Figure 2.3. Vector information for HAL expression clone 
The vector information for the wildtype HAL transcript and the mutant HAL clone is the same. 
The clone contains a wheat germ cell free vector, the ORF length is 1350 bp, and the antibiotic is 
ampicillin. The whole plasmid size differs slightly between clones, the wildtype HAL plasmid 
size is 4769 bp, and the mutant HAL clone is 4714 bp.  
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ampicillin that allows for selection of clones that contain the expression plasmid. Plates were 
covered with parafilm, and stored upside down in incubator at 37°C for 18 hours. 
 
2.7.3.2 Culturing Bacterial Cells 
 To culture bacterial cells, 3 ml of LB media and 3ul of carbenicillin (a synthetic form of 
ampicillin) were added to 50 ml centrifuge tubes, one for each of wildtype DNA and mutant 
DNA. A single colony from the corresponding LB plate was transferred to each tube by adding 
the entire pipette tip. The tubes were shaken at 37°C for five hours. After shaking, the contents of 
the tube was added to a 250 ml flask already containing 100 ml of LB media and 100 ul of 
carbenicillin. The flasks were again shaken at 37°C overnight.  
 
2.7.3.3 Plasmid DNA Purification  
DNA purification was completed using the PrestoTM Midi Plasmid Kit (Geneaid Biotech 
Ltd). The first step in plasmid DNA purification was harvesting the cells. The previously 
cultured bacterial cells were transferred to 50 ml centrifuge tubes and centrifuged at 3,000 x g at 
room temperature for 15 minutes. During centrifugation, a plasmid midi column was placed in a 
new 50 ml centrifuge tube. To equilibrate the tube, 5 ml of PEQ buffer was added to the column 
and allowed to empty by gravity. The flow through was discarded, and the plasmid midi column 
was set aside.   
Once centrifugation was completed, a mixture of 4 ml of resuspension buffer and 40 ul of 
TrueBlue lysis was transferred to the tube with the cell pellet. The cell was resuspended by 
vortexing until all traces of the pellet had been dissolved. 4 ml of lysis buffer was added to the 
resuspended sample then mixed gently by inverting the tube ten times. To neutralize the solution, 
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4 ml of PM3 buffer was added, and the solution was again mixed by inverting the tube ten times. 
The entire solution was then transferred to a collection tube with a filter column. The solution 
was centrifuged at 3,000 x g at room temperature for 2 minutes. The flow through was then 
transferred to the previously equilibrated plasmid midi column and allowed to empty by gravity 
flow, discarding the flow through. The plasmid midi column was then washed with 12 ml of PW 
buffer, and again the column was emptied via gravity flow and the flow through was discarded. 
The plasmid midi column was then placed in a clean 50 ml centrifuge tube, and 8 ml of PEL 
buffer was added to elute the DNA.  
For precipitation, 6 ml of isopropanol was added to the eluted DNA. The solution was 
mixed by inverting and then centrifuged at 3,000 x g at 10°C for 60 minutes. The supernatant 
was then removed, and the DNA pellet was washed with 5 ml of 75% ethanol. The solution was 
centrifuged one final time at 3,000 x g for 30 minutes at 10°C before allowing the DNA pellet to 
dry for 10 minutes. Once the pellet was completely dry, the DNA was resuspended in 200 ul 
RNase free water.  
 
2.7.3.4 Linearization of Plasmid DNA 
An individual master mix was made for both the wildtype and mutant DNA in each step. 
To linearize the purified DNA, 25 ul of DNA, 4ul Reaction Buffer, 2.5 ul NOT1 enzyme, and 8.5 
ul RNase free H2O was added to a 150 ul centrifuge tube, and the solution was incubated at 37°C 
overnight. Following incubation, a phenol/chloroform extract was performed by adding 160 ul of 
RNase free H2O and 200 ul of phenol/chloroform to the incubated solution. The mixture was 
vortexed for 20 seconds and then centrifuged for five minutes. The upper layer was transferred to 
a new centrifuge tube. Next, a chloroform extract was performed by adding 190 ul of chloroform 
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to the upper layer. The mixture was again vortexed for 20 seconds, centrifuged for five minutes 
and then the top layer was transferred to a new tube. The final step in linearization was ethanol 
precipitation. 1:10 the volume of sodium acetate and 3x the volume of 100% ethanol was added. 
This mixture was placed on ice for ten minutes and then centrifuged at 4°C for 20 minutes to 
precipitate the DNA. The DNA pellet was then washed with 100 ul of 70% ethanol and 
centrifuged at 4°C for five minutes. The pellet was left to air-dry before resuspension in 10 ul of 
RNase free H2O. Agarose gel electrophoresis was used to view the DNA products and ensure the 
DNA was linearized.  
 
2.7.3.5 RNA Synthesis  
RNA was synthesized from linearized DNA using the mMESSAGE mMACHINETM T7 
Transcription Kit (Thermo Fisher Scientific). The first step was assembling the capped 
transcription reaction at room temperature. A master mix was made for both the wildtype and 
mutant DNA. The master mix contained 10 ul of 2x NTP/CAP solution, 2 ul of 10x reaction 
buffer, 2 ul of T7 enzyme mix, 1 ug of linearized DNA, and RNase free H2O to make 20 ul. The 
mixture was briefly micro-centrifuged and then incubated at 37°C for two hours. After 
incubation, 1ul of TURBO DNase was added, the solution was mixed and left to incubate at 
37°C for 15 minutes.  
A Poly(A) tailing kit was used to polyadenylate the RNA transcript and ensure stability 
(Thermo Fisher Scientific). The kit adds a >150 base poly(A) tail with the use of E.coli Poly(A) 
Polymerase (E-PAP) and ATP. After incubation, 20 ul of 5xE-PAP buffer, 10 ul of 25 mM 
MnCl2, 10 ul of 10 mM ATP and 36 ul of RNase free H2O was added to the transcription 
reaction. At this point, 1 ul was removed to run on a gel at the end of the experiment to ensure 
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the polyadenylation reaction was successful. After the addition of 4 ul of E-PAP enzyme, the 
reaction was left to incubate at 37°C for one hour.  
Lithium chloride precipitation was used to recover the RNA and remove unincorporated 
nucleotides and proteins. 30 ul of nuclease-free H2O and 30 ul of lithium chloride precipitation 
solution was added to each reaction. Tubes were mixed thoroughly and chilled overnight at         
-20°C. The mixtures were removed from the freezer and centrifuged at 4°C for 15 minutes to 
pellet the RNA. The supernatant was carefully removed, and the RNA pellet was washed with 1 
ml of 70% ethanol. Tubes were recentrifuged for another 15 minutes at 4°C to maximize the 
removal of unincorporated nucleotides. The remaining ethanol was removed, and the RNA was 
resuspended in 20 ul of nuclease-free H2O.  
Agarose gel electrophoresis with bleach was used to view the RNA products. A bleach 
gel provides an alternative method of analyzing RNA while preserving its integrity 202. The 
agarose gel was prepared as described previously with the addition of 500 ul of bleach for every 
50 ul TAE buffer. The final RNA product, and the minus-enzyme control that was reserved 
before adding the E-PAP enzyme, were run next to each other to ensure polyadenylation had 
occurred. The gel was loaded into the electrophoresis chamber and ran at 120 V for 25 minutes. 
The gel was then viewed via an AlphaImager®EP under trans ultraviolet light to assess the 
results of the RNA synthesis. The RNA concentrations were then quantified and stored at -20°C.  
 
2.7.3.6 MO and RNA Injections  
To determine if the previously observed morphant phenotype could be rescued, after the 
administration of hal MO, zebrafish embryos were also injected with the synthesized hal 
wildtype RNA. As a control measure, a separate cohort of embryos were injected with an 
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equivalent dose of mutant RNA rather than the wildtype, to ensure only the latter demonstrated 
rescue of the hemorrhagic phenotype and to demonstrate that the mutation causes loss of 
function.   
Prior to beginning injections, the hal MO was prepared as previously described. The 300 
nmol hal MO was combined with p53 MO and diluted into 4.25 ng/ul aliquots. The aliquots were 
heated for 10 minutes in a 65°C water bath before injections. Approximately 12 ng of hal + p53 
MO was injected into live zebrafish embryos at the one cell-stage. After embryos were injected 
with hal + p53 MO, RNA injections began. Initially, the RNA was diluted to 200 ng/ul, and 
injections were aimed at 400 ng/embryo. Injections were performed carefully to inject RNA 
directly into the cell of each embryo. In total there were four cohorts of embryos, hal + p53 MO, 
wildtype HAL RNA and hal + p53 MO, mutant HAL RNA and hal + p53 MO, and uninjected 
embryos (Figure 2.4).  
Once injections were completed, embryos were cared for in the same way as all other 
MO-mediated gene knockdowns throughout the project. Embryos were stored in petri dishes 
with 1X embryo media and incubated at 37°C. At 24 hours post fertilization, embryos were 
screened to remove any deceased or unfertilized embryos. The embryo media in each petri dish 
was also removed, replaced with PTU media mix, and at 30 hours post fertilization embryos 
were removed from their chorions. Finally, embryos were imaged at 48 and 72 hours post 
fertilization to determine if any hemorrhages were observable. The rescue experiment was 
repeated the same way with a lower concentration of RNA. All subsequent repetitions of the 
experiment used wildtype and mutant RNA diluted to 100 ng/ul, and injections were aimed at 




A Chi-square test with Yates correction was used for statistical analysis of morpholino 
injections throughout the project. The Chi-square test was calculated using a chi-square 
calculator for a 2x2 contingency table from the web-based program Social Science Statistics 203.  
Associations between cohorts were reported as a chi-square statistic with Yates correction and a 
corresponding p-value. 
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mutant HAL RNA 
Uninjected  
hal + p53 MO 
 
hal + p53 MO 
hal + p53 MO & wildtype HAL RNA 
 
hal + p53 MO 
wildtype HAL RNA 
 
 
hal + p53 MO & mutant HAL RNA 
 
hal + p53 MO 
Figure 2.4. MO and RNA injection cohorts 
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3. Results 
3.1 Family Origins 
 This project focused on a cohort of 13 families that originated from NL. All families had 
a strong genetic predisposition to IA, with at least two affected individuals. While the number of 
affected study participants within each family varied, the majority had three or more relatives 
with IA. This created a cohort of 46 affected individuals within the project; the average age of 
initial diagnosis is 50.5 years, and the majority of affected individuals are females (80%). The 
literature suggests that the mode of inheritance of IA is likely variable 61. However, the majority 
of families within this cohort demonstrate inheritance patterns consistent with autosomal 
dominant inheritance. Because the inheritance pattern was more challenging to define in the 
remaining minority of families, all modes of inheritance were considered a possibility. The 
following subsections illustrate the pedigrees of all 13 study families, including a general 
indication of their familial origin and summary of all affected individuals. 
 
3.1.1 Family R1256 
 The Family R1256 originates from the Happy Valley-Goose Bay area of Labrador 
(Figure 3.1). With 12 affected individuals, 11 of whom are study participants, R1256 is by far the 
largest family within the project (Figure 3.2). Only 2/11 affected individuals within R1256 are 
male, and the average age of initial diagnosis is 50.2 years. The proband, Z1013 has two IAs, one 
of which was discovered at 29 years of age due to the SAH that ensued, while the second IA was 
found at age 61. All other affected individuals from R1256 are within the same generation as 













Figure 3.1. Relative geographic family locations 











Figure 3.2. Condensed pedigree of Family R1256 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
AAA are indicated, as well as the patient age at diagnosis. 
 
 
 Unaffected Male 
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* Exome Sequenced  Proband 
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R1256 is autosomal recessive inheritance. However, it could also be autosomal dominant 
inheritance with incomplete penetrance. Various other known environmental factors 
predisposing to aneurysms are prevalent within Family R1256, specifically a history of smoking 
and hypertension (Table 2.1).  
 
3.1.2 Family R1262 
 There is a strong history of IA and AAA in Family R1262. Originating from the Avalon 
Peninsula, the family has four individuals with IA, and two individuals with AAA (Figure 3.3). 
Only 2/4 individuals with IA are study participants, both of whom are female, the proband 
Z1037, and her sister Z991. Their age at initial diagnosis was 56 and 46 years, respectively, and 
neither individual has a known history of any IA associated risk factors. Although not a study 
participant, the paternal grandmother of Z1037 and Z991 also had IA. Furthermore, while neither 
of their parents had IA, they both had AAA. The occurrence of AAA within Family R1262 
complicates the interpretation of inheritance. If the same genetic variant responsible for the 
development of IA is also responsible for the paternal AAA, the mode of inheritance is likely 
autosomal dominant through paternal alleles. However, given the maternal AAA, the possibility 
of maternal inheritance cannot be ignored.  
 
3.1.3 Family R1265 
 Family R1265 represents a smaller kindred within the study, which originates from the 
Avalon Peninsula. DNA was available from two siblings, Z995 and Z994, both who have IA 
(Figure 3.4). The proband, Z995, was diagnosed at 63 years of age and has no other known IA 
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Figure 3.4. Condensed pedigree of Family R1265 
Any individual with a Z identification number indicates a study participant in which 
DNA was available. Individuals with IA and AAA are indicated, as well as the 
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Figure 3.3. Condensed pedigree of Family R1262 
Any individual with a Z identification number indicates a study participant in which 
DNA was available. Individuals with IA and AAA are indicated, as well as the 
patient age at diagnosis. 
 
 86 
and she had no other known IA risk factors.  
 
3.1.4 Family R1276 
 The Family R1276 has origins from the Bay of Islands region, more specifically the north 
shore. R1276 is one of the larger, well-characterized families within the study. There are three 
affected siblings Z1007, Z1015, Z1017, and a vast number of unaffected familial study 
participants as well (Figure 3.5). The average age of initial diagnosis within Family R1276 is 66 
years of age, slightly older than the typical age of onset.  Individual Z1017 also has AAA in 
addition to IA, and all three affected siblings underwent aneurysmal clipping.  
 It was initially understood that there were four affected individuals within Family R1276. 
Individual Z1415, a first-degree, maternal cousin of the other affected individuals (Z1007, 
Z1015, and Z1017), was initially classified as an affected family member. Initial investigations 
identified what appeared to be a tiny middle cerebral artery aneurysm. Subsequent follow-up 
investigations ruled it was not an IA, and Z1415 was reclassified as unaffected.  
 
3.1.5 Family R1277 
 Another very large, well-characterized kindred with a strong predisposition to IA is 
Family R1277. The family has origins in the St. Barbe Straits of the Northern Peninsula. There 
are eight affected individuals within the family, six of whom are study participants, spanning two 
generations (Figure 3.6). The inheritance pattern within R1277 may be autosomal dominant 
inheritance; affected parents have affected offspring without skipping generations. However, the 
inheritance pattern may also be autosomal recessive. Perhaps the mother and father of Z1304 are 
related, which is not unheard of in these very small communities. The affected individuals
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Figure 3.5. Condensed pedigree of Family R1276 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals 
with IA and AAA are indicated, as well as the patient age at diagnosis. 
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Figure 3.6. Condensed pedigree of Family R1277 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA 
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include four males and two females, with an average age of initial diagnosis of 46.6 years of age. 
Individual Z1304, son of Z1305 (also affected), was only 26 when his IA was discovered. The 
majority of affected family members within R1277 did not receive surgical intervention, with the 
exception of Z1355 and Z1353, both of whom underwent surgical clipping. Both Z1355 and 
Z1353 had SAH as a result of their aneurysm rupture.  
 
3.1.6 Family R1357 
 With five family members who have IA, Family R1357 represents another large kindred 
within the study that originates from the western shores of NL. Many affected individuals within 
R1357 also have a history of smoking and hypertension (Table 2.1). All of the affected 
individuals are female, and the average age of initial diagnosis was 51 years of age (Figure 3.7). 
Two affected individuals were relatively young at initial diagnosis; Z1069 and Z1297, who were 
34 and 37, respectively. The mother of Z1297, Z1366, also has an IA and was diagnosed at 45 
years of age. The familial proband Z1054 was initially diagnosed at 46 years old and has three 
IAs. Her maternal cousin, Z1069, also has multiple IAs. One of these IAs ruptured, and a SAH 
resulted. Affected individuals Z1054, Z1069, and Z1366 had their aneurysms clipped, while 






Figure 3.7. Condensed pedigree of Family R1357 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
AAA are indicated, as well as the patient age at diagnosis. 
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3.1.7 Family R1381 
 Originating from the Avalon Peninsula, the inheritance of both IAs and AAAs makes 
Family R1381 a particularly interesting kindred to study (Figure 3.8). While individuals with 
AAAs are not classified as affected study participants, the association between these two types  
of aneurysms is well recognized. The average age of initial diagnosis between the three affected 
siblings Z1133, Z1137, and Z1369 (two females, one male) was 57.3 years of age. Individual 
Z1371, an additional sibling, was diagnosed with AAA at 65 years of age. The inheritance of IA 
within R1381 seems to be coming from the paternal side, as the paternal grandmother of the 
affected individuals had IA. The father of the affected individuals also had an AAA. The 
proband Z1133 has two IAs, one of which ruptured, and a SAH followed. The other IA was 
clipped to prevent further complications. Individual Z1137 also had a SAH due to an IA, before 
the aid of any surgical intervention. 
 
 3.1.8 Family R1383 
 An additional family with origins from NL’s eastern Avalon Peninsula, R1383, has three 
affected individuals, two of whom are study participants (Figure 3.9). Both Z1140 and Z1317 are 
female and were diagnosed with IA at 51 and 31, respectively. No surgical intervention was 
required for either individual. However, Z1140 does have a history of hypertension, DM, and 
smoking.  
 
3.1.9 Family R1385 
 Family R1385 originates from the eastern part of the province, in the Bonavista Bay area. 
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Figure 3.8. Condensed pedigree of Family R1381 
Any individual with a Z identification number indicates a study participant in which DNA was 































Figure 3.9. Condensed pedigree of Family R1383 
Any individual with a Z identification number indicates a study participant in which DNA was available. 
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affected individuals, Z1148 and Z1150 are study participants who were diagnosed with IA at 47 
and 31, respectively (Figure 3.10). The proband, Z1148, has two large IA’s and experienced a 
SAH that was repaired by surgical clipping. Individual Z1150 also has a history of hypertension. 
A small IA was also discovered in individual Z1150, the daughter of Z1148. The third affected 
individual within Family R1385 is a first cousin once removed of Z1150.  
 
3.1.10 Family R1400 
 Another large, well-characterized family, R1400, although unrelated to Family R1277, 
also has origins in the St. Barbe Straits of the Northern Peninsula. Three of the affected study 
participants, Z1159, Z1360, and Z1364, are female, and their average age of initial diagnosis is 
relatively young, at 34.3 years of age (Figure 3.11). Individual Z1364 has two IAs, one of which 
ruptured, causing a SAH. Individuals Z1159 and Z1360 did not require surgical intervention, but 
Z1364 had her aneurysm clipped.  There was no known history of any IA associated risk factors 
in Family R1400. 
 
3.1.11 Family R1888 
 Family R1888 originated from the southwestern tip of the island and has a strong family 
history of IA. Four of six affected family members are study participants, three females and one 
male (Figure 3.12). The average age of initial diagnosis in Family R1888 is 58.8 years of age. 
There is a history of some modifiable IA risk factors within the family, such as smoking and 




Figure 3.10. Condensed pedigree of Family R1385 
Any individual with a Z identification number indicates a study participant in which DNA was available. 
Individuals with IA and AAA are indicated, as well as the patient age at diagnosis. 



















Figure 3.11. Condensed pedigree of Family R1400 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
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Figure 3.12. Condensed pedigree of Family R1888 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
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No other affected individuals within R1888 required surgical intervention for IA. The inheritance 
pattern within R1888 is difficult to interpret.  
 
3.1.12 Family R1893 
 Family R1893 is one of the smaller kindreds within the study, who also originates from 
the Avalon Peninsula. Of the three affected family members within R1893, Z1395 is the only 
study participant (Figure 3.13). There are also multiple unaffected study participants within 
R1893. Three IAs were identified in individual Z1395; the first one was recognized when she 
was 57 years of age. One of her large aneurysms within the anterior communicating artery 
ruptured, causing a SAH. Individual Z1395 had a history of smoking and underwent surgical 
coiling to repair her IA. Another affected individual within R1893 is a first-degree relative once 
removed from Z1395. This individual died of a ruptured IA at only 12 years of age.  
 
3.1.13 Family R2409 
 Family R2409 has origins from the south coast of NL, in an area known as the Coast of 
Bays Region. The two affected study participants Z1582 and Z1584 are sisters, both with two 
IAs that were initially diagnosed at 67 years of age (Figure 3.14). No surgical intervention was 
required for either affected individual, but they both have a history of smoking and hypertension. 
There are many unaffected first-degree relatives of Z1584 and Z1582 who are also study 




Figure 3.13. Condensed pedigree of Family R1893 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA 
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Figure 3.14. Condensed pedigree of Family R2409 
Any individual with a Z identification number indicates a study participant in which DNA 
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3.2 Variant Filtering 
3.2.1 WES Data 
TCAG provided the WES data in annotated variant tables, grouped by family. The first 
filtering step, implemented to reduce the vast number of genetic variants, was to only include 
variants with a read depth greater than 10 from all exomes within a single family. While this 
initial step significantly reduced the number of variants, an average of 42,277 variants per family 
remained.  
 
3.2.2 Preliminary Variant Filtering 
 The exact number of variants that passed filtering criteria per family following each of 
the filtering steps is outlined in Table 3.1. The filtering step most effective in reducing the 
quantity of genetic variants was only including variants with a MAF less than 5%, which were 
also shared by all affected individuals within a family. Later it was decided a more stringent 1% 
allele frequency cut off should be used. Once the filtering criteria was implemented, the genetic 
variants remaining in each family varied anywhere from 2-72 genetic variants. The greater the 
number of affected individuals who were whole exome sequenced within a family, the fewer 
genetic variants that remained. All remaining variants were categorized into high impact or 
moderate impact based upon the effect of the variant on the coding sequence. The high impact 
variant group consisted of frame-shift deletions/insertions, stop-gained/lost, and splice-
acceptor/donors, whereas the moderate impact group consisted of in-frame insertions/deletions, 
missense, and protein-altering mutations. The moderate impact group had the majority of 
variants remaining following initial filtering, ranging anywhere from 2-63 per family. The 
number of high impact variants was slightly lower, ranging anywhere from 0-11 per family. As 
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Family R2409 had only two affected individuals whole exome sequenced, it understandably had 
the highest number of variants remaining post-filtering. There were 72 variants remaining, nine 
of these were high impact, and 63 were moderate impact variants. As expected with such 
stringent filtering criteria, not all families had such a large quantity of variants remaining. Family 
R1357 had the lowest number of variants with only two moderate impacts remaining and no high 
impact variants. 
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Table 3.1. Variant filtering results 
Study Family R1256 R1262 R1265 R1276 R1277 R1357 R1381 R1383 R1385 R1400 R1888 R1893 R2409 
Read depth > 10x 38436 51912 58309 41663 24943 30125 37960 48252 55167 38064 27735 40386 56649 
Shared variants 




319 574 608 352 122 143 224 367 558 237 137 355 628 
 “PASS” in GATK 98 308 348 152 17 8 65 122 300 50 9 164 296 
MAF <1% 51 138 146 66 11 5 29 54 163 27 7 65 168 
Predicted 
deleterious in 4/7 
bioinformatics 
toolsviii 
27 51 54 21 5 2 15 27 58 15 5 29 72 
High Impact 2 10 3 3 1 0 4 6 11 1 1 4 9 
Moderate Impact 25 41 51 18 4 2 11 21 47 14 4 25 63 
 
 
vii The minor allele frequencies reported in ExAC, NHLBI, 1000 Genomes and CG Datasets were used 
viii The bioinformatics predictive criterion is listed in Table 2.3 
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3.2.3 Published IA Candidate Genes 
 The first step in prioritizing candidate variants was to query the remaining variants from 
each family for any of the 68 candidate IA genes published by Farlow et al. (2015) 100. Any 
variants in genes that were identified in both lists were prioritized for further consideration.  Four 
genes were detected in both lists, and the specific variants prioritized are summarized in Table 
3.2. The table also includes the corresponding variant highlighted in the Farlow et al. (2015) 
paper for each candidate gene.  
 The novel, frame-shift mutation ZNF835 (c.378delC; p.I126fs), and the missense 
mutation TAS1R1 (c.1807C>T p.R603C) were detected in all affected family members in Family 
R1381. The TAS1R1 (c.1807C>T p.R603C) variant was previously reported in dbSNP as 
rs41278022 and has a MAF of 0.6307%. The missense variant HAL (c.959C>T; p.T320M), 
which has a MAF of 0.02472% and TBC1D7 (c.866C>T; p.P289L), that has a MAF of 
0.00244%, were also prioritized as they were detected in all affected family members in R1262 
and R1256 respectively. The HAL (c.959C>T; p.T320M) variant was reported as rs200270904 in 
dbSNP and the TBC1D7 (c.866C>T; p.P289L) variant was unreported.  
 In addition to the paper published by Farlow et al. (2015), the remaining list of variants 
was also cross referenced with the list of candidate IA genes published by Yan et al. (2015) 
(Table 3.2) 101. There were two missense variants identified, one in DSG1 and the other in TTN. 
The DSG1 (c.2215A>G; p.I739V) variant is reported in dbSNP as rs78995670, has a MAF of 
0.4061%, and was detected in all affected family members in Family R1256. Alternatively, the 
TTN (c.22420G>A; p.A7474T) variant is unreported in dbSNP, has a MAF of 0.01256%, and 
was detected in all affected family members in Family R1265. Table 3.2 also includes the 
corresponding variant highlighted in the Yan et al. (2015) paper for both candidate genes.  
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Table 3.2. Details of variants in published IA candidate genes  
Gene Family Chromosome Position 
Variant Details 




R1262 12q23.1 c.959C>T p.T320M (NM_00125833) rs200270904 nsSNV 
0.0002472 
(30/121346) 
Farlow et al. 
(2015) 12q23.1 
c.G1472T p.G491V 




R1381 1p36.31 c.1807C>T p.R603C (NM_138697) rs41278022 nsSNV 
0.006307 
(748/118590) 
Farlow et al. 
(2015) 1p36.31 
c.C344T p.T115M 




R1256 6p24.1 c.866C>T p.P289L (NM_001143965) N/A nsSNV 
0.0000244 
(3/119770) 
Farlow et al. 
(2015) 6p24.1 
c.C413A p.A138D 




R1381 19q13.43 c.378delC p. I126fs (NM_001005850) N/A 
frameshift 
deletion novel 
Farlow et al. 
(2015) 19q13.43 
c.G753C p.E251D 




R1256 18q12.1 c.2215A>G p.I739V (NM_001942) rs78995670 nsSNV 
0.004061 
(493/121408) 
Yan et al. 
(2015) 18q12.1 
c.2134C>T p.R712C 








N/A nsSNV 0.0001256 (15/119380) 













ix MAF as reported in ExAC 
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3.2.4 Variants Shared in Multiple NL Families 
 Further variant prioritization included any variants detected in all affected family 
members, in two or more study families. Of the five variants prioritized (summarized in Table 
3.3), two of them were nonsynonymous single nucleotide variants, FARSA (c.340C>T; 
p.R114W), and METTL20 (c.583C>G; p.L195V). The FARSA (c.340C>T; p.R114W) variant 
was previously reported in dbSNP as rs117345957 and has a MAF of 0.2098%. The METTL20 
(c.583C>G; p.L195V) variant is reported as rs11051523 and has a MAF of 0.2728%.  
Furthermore, three stop-gain mutations were also prioritized. MST1R (c.4129C>T; 
p.Q1377X) is a novel variant, present in two unrelated study families and was previously 
reported in dbSNP as rs368400291. The variant OR2T35 (c.957_958insTG; 
p.I320_R321delinsX) was unreported in dbSNP but was identified in three unrelated study 
families. The MAF of the OR2T35 (c.957_958insTG; p.I320_R321delinsX) variant, as reported 
in the exome data, is 0.0298%. Finally, the novel variant IGSF3 (c.1784G>A; p.W595X) was 
reported in dbSNP as rs61730489 but was identified in six study families. Detecting this variant 
in such a large number of study families prompted the manual search of each variant in dbSNP. 
This step would avoid prioritizing false-positive variants. The manual search of IGSF3 
(c.1784G>A; p.W595X) detected that the variant was flagged as “suspect” in dbSNP. Variants 
are flagged as a suspect in dbSNP if located in paralogous regions that could result in mapping 
artifacts or if there are sequencing errors or computation artifacts. Thus IGSF3 (c.1784G>A; 
p.W595X) was not considered for further investigation. 
  The final variant prioritization step included identifying any different variants, in the 
same gene, present in multiple families (Table 3.3). Two different variants were prioritized in 
each of ADGRV1, MADD, PTPN13, and TRPM1. The prioritized variants in ADGRV1, MADD,  
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Table 3.3. Details of variants shared in multiple NL families  
Gene Family Chromosome Position 
Variant Details 
(Transcript ID) rsID Effect 
MAF x 
(Allele Count) 
FARSA R1256 R2409 19p13.2 
c.340C>T p.R114W 














rs61730489 stopgain novel 
METTL20 R1277 R1385 12p11.21 
c.583C>G p.L195V 
(NM_001135863) rs11051523 nsSNV 
0.002728 
(331/121356) 













N/A stopgain 0.000298 
ADGRV1 


















rs61755074 nsSNV 0.001319 (160/121332) 
PTPN13 







rs367673560 nsSNV 0.00005014 (6/119672) 
TRPM1 







N/A stopgain 0.00000817 (1/120754) 
 
 
x MAF as reported in ExAC 
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and PTPN13 are missense mutations. The ADGRV1 (c.1522A>C; p.I508L) variant was detected 
in Family R1262 has a MAF of 0.261% and was reported in dbSNP as rs6174480. The 
alternative variant within the ADGRV1 gene, ADGRV1 (c.6317C>T; p.A2106V), was detected in 
Family R1276, has a MAF of 0.1622% and was reported in dbSNP as rs186999408.  One of the 
variants prioritized in the MADD gene, MADD (c.3869G>A; p.R1290H), is a novel variant that 
was not previously reported in dbSNP but was detected in Family R1262. Alternatively, the 
variant MADD (c.3418G>A; p.A1161T) was detected in Family R1265, has a MAF of 0.1319%, 
and was reported in dbSNP as rs61755074. Both variants in the PTPN13 gene – PTPN13 
(c.3563C>T; p.T1188I) that has a MAF of 0.1484% and PTPN13 (c.7336C>T; p.R2446C) that 
has a MAF of 0.005014% – were previously reported in dbSNP as rs186651045 and 
rs367673560 respectively. Finally, the rare missense mutation TRPM1 (c.413T>C; p.L138P) was 
detected in Family R1256, has a MAF of 0.009802%, and was previously reported dbSNP as 
rs191205969. The additional TRMP1 variant prioritized, TRPM1 (c.4237G>T; p.E1413X) is a 
stop-gain mutation that was not previously reported in dbSNP. This variant was detected in 
Family R1381 and had the lowest MAF of all prioritized variants at 0.000817%.  
 The stringent steps of the variant filtering strategy combined with the specific variant 
prioritization approach reduced the thousands of genetic variants to a list of 19 candidate 
variants. With the exception of IGSF3 (c.1784G>A; p.W595X), that was excluded from further 






3.3 Validation of Candidate Variants 
 The use of Sanger sequencing in conjunction with WES allows validation that candidate 
variants are real genetic variants and not false-positive calls that succeeded in passing filtering 
criteria.  In addition to validation purposes, Sanger sequencing can help determine if a candidate 
variant segregates with all the affected individuals in a family. The following subsections 
provide the Sanger sequencing results for all 18-candidate variants, in 14 genes, which are 
summarized in Table 3.4. The initial round of Sanger sequencing was exclusively used to 
validate each variant, and thus only affected individuals within each family were sequenced. Of 
the 18 candidate variants, six variants, in six genes (TBC1D7, DSG1, FARSA, OR2T35, MADD, 
TRPM1) were not validated upon Sanger sequencing and thus were not prioritized for further 
investigation. A summary of the familial segregation for the additional 12 candidate variants that 
were validated is described in section 3.4.  
 
3.3.1 DSG1 (c.2215A>G; p.I739V) 
 The filtering approach applied to the WES data did not employ any assumptions about 
biological processes or pathways. However, the known functionality of Desmoglein 1 (DSG1), in 
addition to Yan et al. (2015) identifying it as a candidate IA gene, made it an exceptionally 
noteworthy candidate to investigate 101. As part of the desmoglein family, these cadherin-like 
adhesion molecules are an integral part of the desmosome 204. The ability of these intracellular 
junctions to resist mechanical stress provides strength to various tissues 205. Mutations in DSG1 
have been associated with the syndrome erythroderma, congenital with palmoplantar 
keratoderma, hypotrichosis and hyper IgE (EPKHE) which is characterized by extensive 
dermatitis, metabolic issues and various allergies 206.  
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 The DSG1 (c.2215A>G; p.I739V) variant was found to segregate with 4/11 affected 
individuals in Family R1256 via Sanger sequencing (Figure 3.15). Two siblings Z929 and Z1013 
are carriers of the variant, as is their half-sister Z1501 (same father). Z1471 is a paternal cousin 
of Z929, Z1013, and Z1501 and is also a carrier of DSG1 (c.2215A>G; p.I739V).  A niece of 
Z929 and Z1013 has a daughter, Z1459, who also has an IA, but she does not have the DSG1 
(c.2215A>G; p.I739V) variant. The six additional affected family members, Z1522, Z1406, 
Z1441, Z1390, Z1405, and Z1448 are not carriers of the variant, and thus DSG1 (c.2215A>G; 
p.I739V) was not prioritized for further investigation. 
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Table 3.4. Summary of segregation for all 18 candidate variants 
 
xi MAF as reported in GnomAD were also included for reference 
xii Individual Z1371 has an AAA not an IA 
Gene Variant Details (Transcript ID) 
MAF 
(Allele Count) Family 
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R1385 2/2 1/1 Z1148, Z1150 Z1149 












novel 0.00001988 (5/251462) 
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Figure 3.15. DSG1 (c.2215A>G; p.I739V) segregation in affected family members of R1256 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 




 Affected Female 
 
 
* Exome Sequenced  Proband 
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3.3.2 TBC1D7 (c.866C>T; p.P289L) 
 TBC1 Domain Family Member 7 (TBC1D7) encodes a subunit of the tuberous sclerosis 
TSC1-TSC2 complex that is involved in cell growth and differentiation 207. Previously described 
mutations in the TBC1D7 gene are associated with the autosomal recessive growth disorder 
megalencephaly 208. Farlow et al. (2015) highlighted a mutation in the TBC1D7 gene as a 
candidate IA variant that is different from the variant identified in Family R1256 100. DNA 
sequence chromatograms generated from Sanger sequencing revealed TBC1D7 (c.866C>T; 
p.P289L) only segregates with 4/11 affected individuals in Family R1256. These four individuals 
include two half-sisters, Z929 and Z1501 (same father), and two of their paternal cousins, Z1522, 
and Z1471. The remaining affected individuals, Z1013, Z1459, Z1406, Z1441, Z1390, Z1405, 
and Z1448, are not carriers of the variant (Figure 3.16). This segregation pattern did not provide 
confidence in the contribution of TBC1D7 (c.866C>T; p.P289L) to IA development, and thus it 
was not considered for further investigation in this population.  
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Figure 3.16. TBC1D7 (c.866C>T; p.P289L) segregation in affected family members in R1256 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
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3.3.3 FARSA (c.340C>T; p.R114W) 
 The variant identified in Phenylalanyl-TRNA Synthetase Alpha Subunit (FARSA) 
(c.340C>T; p.R114W), was found in two unrelated NL families, R2409 and R1256. FARSA 
belongs to a family of enzymes that use amino acids to charge a cognate tRNA 209. Mutations in 
FARSA are associated with sarcocystosis and myiasis, two related parasitic infections 210,211. Of 
the 11 affected individuals Sanger sequenced from Family R1256, the FARSA (c.340C>T; 
p.R114W) variant was found in seven individuals (Figure 3.17). The sisters Z1522 and Z1471 
are both carriers of the variant, as well as their maternal cousins, Z1405, Z1406, and Z1441. 
These three affected siblings have an additional affected sister Z1390 who is not a carrier of the 
FARSA (c.340C>T; p.R114W) variant. Another affected family member, Z1448, is their half–
brother (same father), and he too carries the variant. The FARSA variant was absent from two 
other affected siblings, Z929 and Z1013. Conversely, their half-sister Z1501, who is also 
affected, is a carrier of FARSA (c.340C>T; p.R114W). The DNA from Z1459 was also Sanger 
sequenced, and the FARSA (c.340C>T; p.R114W) variant was absent.  
 In addition to Family R1256, FARSA (c.340C>T; p.R114W) was also identified in 
Family R2409, and Sanger sequencing validated the variant segregated with both affected sisters 
Z1582 and Z1584 (Figure 3.18). Nonetheless, the segregation of FARSA (c.340C>T; p.R114W) 





Figure 3.17. FARSA (c.340C>T; p.R114W) segregation in affected family members of R1256 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
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Figure 3.18. FARSA (c.340C>T; p.R114W) segregation in affected family members of R2409 
Any individual with a Z identification number indicates a study participant in which DNA was 
available. Individuals with IA and AAA are indicated, as well as the patient age at diagnosis. 
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3.3.4 OR2T35 (c.957_958insTG; p.I320_R321delinsX) 
 Olfactory Receptor Family 2 Subfamily T Member 35 (OR2T35) encodes a family of G-
protein coupled receptors, olfactory receptor proteins. There are various families of G-protein 
coupled receptors, and this particular gene family is one of the largest in the human genome 
212,213. Based on the current literature, no disorders have been associated with the ORT2T35 gene 
thus far. WES data identified the OR2T35 (c.957_958insTG; p.I320_R321delinsX) variant in all 
affected individuals in three different study families, R1262, R1277, and R2409.  
 Sanger sequencing of affected individuals in all three families revealed the OR2T35 
(c.957_958insTG; p.I320_R321delinsX) variant was not in any affected individuals. As with any 
sequencing platform, there are errors associated with TCAG variant calls, and false-positive calls 
do occur. The variant filtering criteria would ideally eliminate all false-positive calls. However, 
that is not always a realistic expectation and exemplifies why validating variants with Sanger 
sequencing is a necessary step in WES projects. The OR2T35 (c.957_958insTG; 
p.I320_R321delinsX) variant was not validated via Sanger sequencing and was deemed a false-
positive variant call. 
 
3.3.5 MADD (c.3869G>A; p.R1290H) & MADD (c.3418G>A; p.A1161T) 
 MAP Kinase Activating Death Domain (MADD) encodes a death domain adaptor protein 
that is involved in the activation of the apoptotic signal 214. Distinctive isoforms of MADD play 
different roles in the regulation of cell death, survival, and proliferation 215. However, there are 
no disorders currently associated with MADD 216. Two different mutations in MADD passed the 
variant filtering criteria and segregated with IA in two unrelated study families according to 
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WES data. The MADD (c.3869G>A; p.R1290H) variant was identified in Family R1262 and 
MADD (c.3418G>A; p.A1161T) was identified in Family R1265. 
 Sanger sequencing confirmed MADD (c.3418G>A; p.A1161T) in Family R1265. Both 
affected individuals Z994 and Z995 are carriers of the variant (Figure 3.19). Despite the 
validation of MADD (c.3418G>A; p.A1161T) in Family R1265, the additional MADD 
(c.3869G>A; p.R1290H) variant did not segregate with all affected individuals in Family R1262. 
Affected individual Z1037 is a carrier of MADD (c.3869G>A; p.R1290H), but the variant was 
absent from Z991 (Figure 3.20). Because variant prioritization criteria required all affected 
individuals to be carriers of the variant of interest, MADD variants were not prioritized for 
further investigation. 
 
3.3.6 TRPM1 (c.413T>C; p.L138P) & TRPM1 (c.4237G>T; p.E1413X) 
 Two different variants in the gene Transient Receptor Potential Cation Channel 
Subfamily M Member 1 (TRPM1) passed all variant filtering criteria and were found in two 
unrelated NL families. WES data identified the variant TRPM1 (c.413T>C; p.L138P) in Family 
R1256, and the variant TRPM1 (c.4237G>T; p.E1413X) in Family R1381. TRPM1 encodes a 
cation channel protein that is thought to play a role in melanin synthesis 217,218. The gene has 
various identified biological functions. Decreased expression of the TRPM1 protein is used as a 
marker of melanoma metastasis and furthermore, autosomal recessive congenital stationary night 
blindness is caused by specific TRPM1 mutations 219–221.  
 The DNA sequence chromatograms generated from Sanger sequencing the DNA of 
affected individuals in Family R1381 validated the TRPM1 (c.4237G>T; p.E1413X) variant. 




Figure 3.19. MADD (c.3418G>A; p.A1161T) segregation in affected family 
members of R1265 
Any individual with a Z identification number indicates a study participant in which 
DNA was available. Individuals with IA and AAA are indicated, as well as the patient 
age at diagnosis. 
 
Figure 3.20. MADD (c.3869G>A; p.R1290H) segregation in affected family 
members of R1262 
Any individual with a Z identification number indicates a study participant in which 
DNA was available. Individuals with IA and AAA are indicated, as well as the patient 
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sibling, Z1371, who has AAA, is also a carrier of the variant (Figure 3.21).  
Sanger sequencing was then completed in Family R1256 to validate the additional variant 
TRPM1 (c.413T>C; p.L138P) (Figure 3.22). The DNA was available from 11 affected 
individuals in Family R1256. Sanger sequencing identified that only 3/11 affected members were 
carriers of the TRPM1 (c.413T>C; p.L138P) variant. This included half-sisters Z929 and Z1501, 
as well as their paternal cousin Z1471. Despite the fact that TRPM1 (c.4237G>T; p.E1413X) 
segregated with all affected individuals in Family R1381, the segregation within Family R1256 


















Figure 3.21. TRPM1 (c.4237G>T; p.E1413X) segregation in affected family members of 
R1381 
Any individual with a Z identification number indicates a study participant in which DNA was 
available. Individuals with IA and AAA are indicated, as well as the patient age at diagnosis. 
 124 
 
Figure 3.22. TRPM1 (c.413T>C; p.L138P) segregation in affected family members of R1256 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
AAA are indicated, as well as the patient age at diagnosis. 
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3.4 Familial Segregation 
 The remaining 12 candidate variants from eight genes (TAS1R1, HAL, ZNF835, TTN, 
MST1R, METTL20, PTPN13, ADGRV1) segregated with all affected individuals within a family, 
and thus subsequent sequencing of unaffected family members was completed. The following 
sections summarize the familial segregation for all validated variants.  
 
3.4.1 TAS1R1 (c.1807C>T p.R603C) 
 Taste 1 Receptor Member 1 (TAS1R1) encodes a G-protein coupled receptor, a 
component of the amino acid taste receptor T1R1+3 that is activated by tastes perceived as sweet 
222. There are currently no disorders associated with this gene, but Farlow et al. (2015) 
highlighted TAS1R1 as a candidate IA gene. They identified a mutation in TAS1R1 that 
segregated with all affected individuals in an IA study family 100. WES identified a different 
mutation, TAS1R1 (c.1807C>T p.R603C), in the study Family R1381. 
 Sanger sequencing validated the TAS1R1 (c.1807C>T p.R603C) variant as it was present 
in 3/3 affected individuals from Family R1381. All three affected siblings Z1133, Z1137, and 
Z1369 are carriers of the variant. An additional sibling, Z1371, who has an AAA, is not a carrier 
of the variant. The DNA from eight additional unaffected relatives was also available, and 
Sanger sequencing results showed that 4/8 of these unaffected individuals are carriers of TAS1R1 
(c.1807C>T p.R603C) (Figure 3.23).  Individual Z1135 is another sibling of Z1133, Z1137, and 
Z1369 (all affected), and is a carrier of TAS1R1 (c.1807C>T p.R603C) yet showed no IA 
phenotype as of her last CT scan (68 years old). Affected individual Z1137 has three unaffected 
sons who also have the TAS1R1 (c.1807C>T p.R603C) variant, Z1145, Z1368, and Z1370. All 





Figure 3.23. TAS1R1 (c.1807C>T p.R603C) segregation in Family R1381 
Any individual with a Z identification number indicates a study participant in which DNA was available. 
Individuals with IA and AAA are indicated, as well as the patient age at diagnosis or age at last CT scan. 
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their last CT scans.  
 
3.4.2 TTN (c.22420G>A; p.A7474T) 
As it encodes the largest protein in the human body, the Titin (TTN) gene is more 
susceptible to genetic variants by chance, simply due to its size alone 223. However, this cannot 
discount the contribution of TTN mutations to human disease. The titin protein is an abundant 
protein of striated muscle, and thus mutations in TTN cause various familial cardiomyopathies 
224. Titin plays a significant role in the flexibility and structure of muscle, most notably cardiac 
and skeletal muscle, depending on the isoform of titin that is present. The discovery of a new 
titin isoform, the protein sm-titin in smooth muscle demonstrates the potential relevance of titin 
to the vascular smooth muscle of human blood vessels 225,226. Farlow and colleagues identified 
TTN as a candidate IA gene as a variant within TTN segregated with IA in one of their study 
families 100. A different variant than that identified in the Farlow study, TTN (c.22420G>A; 
p.A7474T), was found in Family R1265 after WES.  
 Sanger sequencing of Family R1265 validated that the TTN (c.22420G>A; p.A7474T) 
variant was present in 2/2 affected siblings, Z994, and Z995. The DNA from four additional 
unaffected relatives was also available. Of these four, Z1041 and Z1046, who are siblings of 
Z994 and Z995, are also carriers of the TTN (c.22420G>A; p.A7474T) variant (Figure 3.24).  
The DNA from two additional relatives was also available, Z1050 and Z996, but neither was 
screened to determine a phenotype. Individual Z1050 is the mother of Z994, Z995, Z1041, and 
Z1046, and is also a carrier of TTN (c.22420G>A; p.A7474T). Individual Z996, who is married 





Figure 3.24. TTN (c.22420G>A; p.A7474T) segregation in Family R1265 
Any individual with a Z identification number indicates a study participant in which 
DNA was available. Individuals with IA and AAA are indicated, as well as the patient 
age at diagnosis or age at last CT scan. 
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3.4.3 HAL (c.959C>T; p.T320M) 
Histidine Ammonia-Lyase (HAL) encodes the enzyme that catalyzes the first reaction in 
histidine catabolism. Previously identified mutations in HAL cause histidinemia, a disorder 
characterized by increased levels of histidine that is inherited in an autosomal recessive pattern 
227. The majority of individuals with histidinemia are unaware of their condition, as there is often 
no observable phenotype exhibited 228. In rare circumstances, when histidinemia is combined 
with a lack of oxygen at birth, individuals may be at greater risk of developing intellectual 
disabilities 211.  
 Sanger sequencing validated that the HAL (c.959C>T; p.T320M) variant segregated with 
both affected individuals in Family R1262, one of the smaller study families in this study. The 
affected sisters Z991 and Z1037 are the only study participants (Figure 3.25). The family history 
of these participants revealed an additional sister with IA, as well as their paternal grandmother. 
While neither parent of the siblings had a known IA, they both had AAA. The validation of HAL, 
in combination with the identification of HAL as a candidate IA gene by Farlow et al. (2015), 
provided confidence in prioritizing HAL for further investigation, despite the limited segregation 
data 100. 
 
3.4.4 ZNF835 (c.378delC; p.I126fs) 
Resembling many zinc-finger proteins, Zine Finger Protein 835 (ZNF835) is thought to 
be involved in transcriptional regulation 229. The data available regarding ZNF835 is limited, and 
there are no disorders currently associated with this gene. However, Farlow et al. (2015) did 
identify ZNF835 as a candidate IA gene 100. The specific variant identified within Family R1381 




Figure 3.25. HAL (c.959C>T; p.T320M) segregation in Family R1262 
Any individual with a Z identification number indicates a study participant in which 
DNA was available. Individuals with IA and AAA are indicated, as well as the 
patient age at diagnosis or age at last CT scan. 
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Sanger sequencing results identified that all three affected siblings within Family R1381 
are carriers of ZNF835 (c.378delC; p.I126fs). The affected siblings Z1133, Z1137, and Z1369 
also have a brother with an AAA (Z1371), and he too is a carrier of this ZNF835 variant.  
Sanger sequencing of the eight unaffected relatives in Family R1381 was completed 
following the validation of ZNF835 (c.378delC; p.I126fs) and revealed the absence of the variant 
in 7/8 unaffected relatives (Figure 3.26). Individual Z1370, the son of Z1137 (affected), was 
found to have the ZNF835 (c.378delC; p.I126fs) variant but was only 25 at the time of his last 
CT scan.  
 
3.4.5 METTL20 (c.583C>G; p.L195V) 
 A protein lysine methyltransferase is encoded by METTL20, previously known as 
Electron Transfer Flavoprotein Beta Subunit Lysine Methyltransferase (ETFBKMT) 230,231. 
Cellular metabolism may be a functional role of the METTL20 gene, and there are no disorders 
currently associated with a loss of enzyme activity. The variant within METTL20 identified by 
WES, METTL20 (c.583C>G; p.L195V), was identified in two unrelated NL families, R1385 and 
R1277.   
 METTL20 (c.583C>G; p.L195V) segregated with all affected individuals from Family 
R1277. Three affected siblings, Z1353, Z1354, and Z1008, are all carriers of the variant, as well 
as their maternal cousins Z1305 and Z1355. Individual Z1305 has an affected son, Z1304, who 
also has the METTL20 (c.583C>G; p.L195V) variant. The DNA was also available from eight 
unaffected relatives in R1277, and Sanger sequencing discovered METTL20 (c.583C>G; 
p.L195V) was absent from 7/8 (Figure 3.27). The one unaffected relative with the METTL20 
variant is Z1359. Individual Z1358 is the mother of Z1353, Z1354, and Z1008 and was also a  
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Figure 3.26. ZNF835 (c.378delC; p.I126fs) segregation in Family R1381 
Any individual with a Z identification number indicates a study participant in which DNA was 
available. Individuals with IA and AAA are indicated, as well as the patient age at diagnosis or 
age at last CT scan. 
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Figure 3.27. METTL20 (c.583C>G; p.L195V) segregation in Family R1277 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA 
and AAA are indicated, as well as the patient age at diagnosis or age at last CT scan. 
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study participant. She also was found to be a carrier of METTL20 (c.583C>G; p.L195V) but was 
never screened to determine a phenotype.  
The METTL20 (c.583C>G; p.L195V) variant was also identified in Family R1385. 
Furthermore, Sanger sequencing validated METTL20 (c.583C>G; p.L195V) segregated with 
both affected individuals, Z1148, and Z1150 (Figure 3.28). Individual Z1149 was a sister of 
Z1150 and was the only unaffected study participant in R1385. Sanger sequencing the DNA of 
Z1149 revealed she too is a carrier of METTL20 (c.583C>G; p.L195V). However, she was only 
41 at the time of her last CT scan. The late onset of IA makes it challenging to assume a 
seemingly unaffected individual would not eventually develop an IA.  
 
3.4.6 MST1R (c.4129C>T; p.Q1377X) 
 Macrophage Stimulating 1 Receptor (MST1R) encodes a cell surface receptor for 
macrophage stimulating protein 232. This cell surface receptor is highly expressed in the ciliary 
epithelia of the lung, where it is thought to be involved in host defense 233. The novel, stopgain 
mutation MST1R (c.4129C>T; p.Q1377X) was identified in Family R1262, as well as Family 
R1385, via WES. Sanger sequencing validated the MST1R (c.4129C>T; p.Q1377X) variant in 
both affected individuals Z991 and Z1037 from Family R1262. While R1262 does have a strong 
family history of both IA and AAA, Z991 and Z1037 are the only familial study participants 
(Figure 3.29).  
 Sanger sequencing revealed the variant segregated with both affected individuals Z1148 
and Z1150 (Figure 3.30). Individual Z1149 is the only unaffected study participant within 
Family R1385, and she too is a carrier of the MST1R (c.4129C>T; p.Q1377X) variant. Notably, 






Figure 3.28. METTL20 (c.583C>G; p.L195V) segregation in Family R1385 
Any individual with a Z identification number indicates a study participant in which DNA was available. 
Individuals with IA and AAA are indicated, as well as the patient age at diagnosis or age at last CT scan. 
 




















Figure 3.29. MST1R (c.4129C>T; p.Q1377X) segregation in Family R1262 
Any individual with a Z identification number indicates a study participant in which 
DNA was available. Individuals with IA and AAA are indicated, as well as the 




Figure 3.30. MST1R (c.4129C>T; p.Q1377X) segregation in Family R1385 
Any individual with a Z identification number indicates a study participant in which DNA was available. 








* Exome Sequenced  Proband 
 
 138 
3.4.7 ADGRV1 (c.1522A>C; p.I508L) & ADGRV1 (c.6317C>T; p.A2106V) 
The ADGRV1 protein is a member of the G-protein coupled receptor superfamily. 
Mutations in Adhesion G Protein Coupled Receptor V1 (ADGRV1) are associated with an 
autosomal dominant form of familial febrile seizures as well as Usher syndrome, which 
demonstrates autosomal recessive inheritance. 198,234,235. Two different variants in the ADGRV1 
gene were found in two unrelated NL families. Sanger sequencing confirmed ADGRV1 
(c.1522A>C; p.I508L) was present in 2/2 affected individuals in Family R1262. The family has 
three affected sisters, yet DNA was only available from two, Z991 and Z1037, both of whom are 
carriers of the variant (Figure 3.31).  
The alternative ADGRV1 (c.6317C>T; p.A2106V) variant was identified in Family 
R1276. Sanger sequencing confirmed the variant segregated in 3/3 affected siblings, Z1015, 
Z1017, and Z1007 (Figure 3.32). The validation of ADGRV1 (c.6317C>T; p.A2106V) in all 
affected individuals from Family R1276, prompted the sequencing of DNA from unaffected 
relatives as well. This would provide a better representation of the variant segregation within the 
family (Figure 3.33). Family R1276 exemplifies one of the large, well-characterized families we 
have available within the study. The DNA was available from 52 unaffected relatives, all of 
whom were screened to determine a phenotype. Individual Z1415 was initially classified as an 
affected family member. However, subsequent follow-up investigations ruled there was no IA, 
and Z1415 was reclassified as unaffected. His original classification as an affected study 
participant contributed to the widespread number of unaffected study participants, as relatives 
had already been recruited from that side of the family. Sanger sequencing revealed 2/52 
unaffected individuals, Z1035 and Z1027, are carriers of ADGRV1 (c.6317C>T; p.A2106V). 



















Figure 3.31. ADGRV1 (c.1522A>C; p.I508L) segregation in Family R1262 
Any individual with a Z identification number indicates a study participant in which DNA 
was available. Individuals with IA and AAA are indicated, as well as the patient age at 












Figure 3.32. ADGRV1 (c.6317C>T; p.A2106V) segregation in affected family members of Family R1276 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals 
with IA and AAA are indicated, as well as the patient age at diagnosis or age at last CT scan. 
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Figure 3.33. ADGRV1 (c.6317C>T; p.A2106V) segregation in Family R1276 
Any individual with a Z identification number indicates a study participant in which DNA was available. Individuals with IA and 
AAA are indicated, as well as the patient age at diagnosis or age at last CT scan. 
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nephew of Z1015. These two seemingly unaffected study participants were 31 and 30, 
respectively, at the time of their latest CT scans. However, the late onset of IA makes it difficult 
to assume these are truly unaffected individuals who would not eventually develop an IA. The 
segregation of both ADGRV1 (c.1522A>C; p.I508L) and ADGRV1 (c.6317C>T; p.A2106V) 
provided assurance that further investigation into their possible involvement in IA development 
was worth pursuing. 
 
3.4.8 PTPN13 (c.3563C>T; p.T1188I) & PTPN13 (c.7336C>T; p.R2446C) 
 The  Protein Tyrosine Phosphatase Nonreceptor Type 13 (PTPN13) gene, encodes a 
member of the protein tyrosine phosphatase family of signaling molecules 236.  While various 
functions of PTPN13 have been evaluated, such as its role in apoptosis, tumor suppression, the 
mitotic cycle, cell migration, and differentiation, gaps still remain in our knowledge of PTPN13 
236–239. WES exposed two different mutations in the PTPN13 gene. The variant PTPN13 
(c.3563C>T; p.T1188I) was identified in Family R1381, and the variant c.7336C>T (p.R2446C) 
was identified in Family R1385.  
 The PTPN13 (c.3563C>T; p.T1188I) variant was validated in 3/3 affected individuals 
from Family R1381 via Sanger sequencing. Three affected siblings, Z1133, Z1137, and Z1369, 
are all carriers of PTPN13 (c.3563C>T; p.T1188I). Their additional sibling, Z1371, who has an 
AAA, is also a carrier of the PTPN13 (c.3563C>T; p.T1188I) variant. DNA was also available 
from eight additional unaffected relatives, and 4/8 of these individuals are carriers of the 
PTPN13 (c.3563C>T; p.T1188I) variant (Figure 3.34). Two of the four individuals, Z1145 and 
Z1368, are sons of Z1137 (affected) who were respectively 25 and 28 years old at the time of 
their last CT scans. The other two unaffected carriers of PTPN13 (c.3563C>T; p.T1188I), Z1143 
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and Z1134, are the daughters of Z1133 (affected) and were 39 and 30 respectively at the time of 
their last CT scans. 
 Family R1385 has two affected study participants, Z1148 and Z1150. Sanger sequencing 
validated the PTPN13 (c.7336C>T; p.R2446C) variant in both of these affected individuals. 
Sanger sequencing was then completed on the one unaffected family member, Z1149, and she is 





Figure 3.34. PTPN13 (c.3563C>T; p.T1188I) segregation in Family R1381 
Any individual with a Z identification number indicates a study participant in which DNA was 
available. Individuals with IA and AAA are indicated, as well as the patient age at diagnosis or 




Figure 3.35. PTPN13 (c.7336C>T; p.R2446C) segregation in Family R1385 
Any individual with a Z identification number indicates a study participant in which DNA was available. 




 Affected Female 
 
 
* Exome Sequenced  Proband 
 
 146 
3.5 Population Controls 
 To determine the prevalence of the top candidate variants in the NL population, 100 
population controls from the NFCCR were Sanger sequenced for each of the six prioritized 
variants (Table 3.5). Because the TTN gene was still being considered for functional analysis, 
population controls were also sequenced for the variant TTN (c.22420G>A; p.A7474T). For the 
gene ADGRV1, analysis of two different mutations was required, and thus 100 population 
controls were sequenced for each variant. The candidate variants HAL (c.959C>T; p.T320M), 
METTL20 (c.583C>G; p.L195V), TTN (c.22420G>A; p.A7474T) and ADGRV1 (c.1522A>C; 
p.I508L) were absent from 100 NL population controls. The other ADGRV1 variant, ADGRV1 
(c.6317C>T; p.A2106V) was identified in 1/100 NL population controls, as well as the variants 
in ZNF835 (c.378delC; p.I126fs) and MST1R (c.4129C>T; p.Q1377X).  
As the project progressed, it became apparent that HAL (c.959C>T; p.T320M) was 
emerging as the primary candidate variant. Due to the lack of unaffected study participants 
within Family R1262, 200 additional population controls were Sanger sequenced, which 










Table 3.5. NL control sequencing data of functional candidate variants 
Gene Variant Details (Transcript ID) Family 
MAF 


















































xiii Functional analysis revealed HAL (c.959C>T; p.T320M) was emerging as the primary candidate variant. Due to 
the lack of unaffected study participants within Family R1262, 200 additional population controls were Sanger 
sequenced 
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3.6 Functional Candidates 
 Once Sanger sequencing was completed for all 18 candidate variants, the familial 
segregation of each variant was analyzed. In addition to segregating with all affected individuals 
within a family, variants also needed to be absent from a large percentage of unaffected 
individuals within the family to be considered for further functional analysis. There are some 
limitations to such stringent segregation criteria. However, time and financial constraints 
required that potential candidate variants be prioritized, as not every variant could be 
functionally analyzed. Of the 12 candidate variants from eight genes (TAS1R1, HAL, ZNF835, 
TTN, MST1R, METTL20, PTPN13, ADGRV1) that segregated with all affected individuals within 
a family, six variants from five genes (HAL, ZNF835, MST1R, METTL20 and ADGRV1) met the 
segregation criteria, and thus were prioritized for further investigation. Although the TTN variant 
(c.22420G>A; p.A7474T) was found in 4/8 unaffected relatives in Family R1381, the biological 
function of this gene caused it to remain a noteworthy candidate, and it was initially considered 











3.7 Morpholino Mediated Genetic Knockdowns 
 To evaluate the role of each prioritized candidate variant, antisense MOs were used to 
knockdown the homologous gene in a zebrafish model. Initially, all six candidate genes, 
including TTN, planned to be evaluated using this model. Zebrafish have emerged as an 
exceptional model organism for studying genetic disease. The cerebral vasculature is similar to 
that of humans, their transparent embryos allow for visualization of this vasculature, and their 
genome is highly conserved with that of humans 117. However, the additional round of whole 
genome duplication the zebrafish has undergone resulted in several gene duplications. The TTN 
gene has two orthologs within the zebrafish genome, ttna, and ttnb 240. Complicating matters 
further, the large size and alternative splice sites of TTN requires the use of four antisense MOs 
for gene knockdown 241. Previous work with TTN in zebrafish produced morphant embryos with 
severe cardiac problems, some of which included embryos without a functioning heart 242.  The 
cardiac issues that arise in these zebrafish morphants make it hard to differentiate if 
hemorrhaging is the result of the genetic knockdown or secondary to the cardiac dysfunction 240. 
The foreseeable complexity of the TTN knockdown requires more exploration that could be 
pursued in the future, but was not done so in this thesis.  
 
3.7.1 ZNF835   
 Although approximately 70% of all human genes have a clear orthologue within the 
zebrafish genome, this is not the case for all human genes 128. There is no clear zebrafish 
orthologue for ZNF835, and thus MO-mediated gene knockdown could not be completed. As the 
ZNF835 (c.378delC; p.I126fs) variant appears to be an exceptional candidate variant genetically, 
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finding an alternative route to functionally evaluate its role in IA development would be worth 
future pursuit.  
 
3.7.2 ADGRV1 & METTL20 
 The initial MO-mediated gene knockdowns were completed by injecting zebrafish 
embryos at the one–cell stage, with two different doses of adgrv1 or control MO. Embryos were 
then imaged to see if a dose-dependent hemorrhagic phenotype was observable (Figure 3.36). 
Knockdown of the ADGRV1 ortholog (adgrv1) did not produce a significant hemorrhagic 
phenotype (p=0.451), and thus no further MO injections were completed (Table 3.6). The chi-
square test was used to determine the difference in proportion of hemorrhaging and non-
hemorrhaging embryos. The chi-square statistic with Yates correction was 0.568 with a p-value 
of 0.451. Similarly, the MO-mediated gene knockdown of the METTL20 zebrafish ortholog 
(mettl20) also did not produce a significant hemorrhagic phenotype (p=0.807) compared to that 
of the control morphants (Table 3.6). The chi-square statistic with Yates correction was 0.0595 
with a p-value of 0.807. Thus, no additional MO injections were completed.  
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Table 3.6. Hemorrhage prevalence induced by varying doses of adgrv1 or mettl20 MO 
Treatment Dose Number of Embryos Injected 




adgrv1 MO 3 ng 27 2 7.41% 
adgrv1 MO 9 ng 24 0 0.00% 
mettl20 MO 3 ng 47 2 4.26% 
mettl20 MO 9 ng 21 0 0.00% 
Control MO 9 ng 62 1 1.61% 












Figure 3.36. Knockdown of adgrv1 & mettl20 on zebrafish vasculature 
The top images (A-D) show zebrafish embryos 48 hours post fertilization that were injected with 
various doses of control MO (A and B), adgrv1 MO (C) or mettl20 MO (D). The difference in 
hemorrhage prevalence (E) between control and adgrv1 morphants was not significant (P=0.451). 
The difference in hemorrhage prevalence (F) between control and mettl20 morphants was also not 
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3.7.3 MST1R  
 The whole genome duplication of the zebrafish genome resulted in two MST1R 
orthologs, mst1ra and mst1rb. Zebrafish embryos were examined for a hemorrhagic phenotype 
after the simultaneous knockdown of mst1ra and mst1rb, as well as after the knockdown of only 
one paralog (mst1ra or mst1rb). No hemorrhagic phenotype occurred following individual 
mst1ra or mstr1rb knockdowns. However, the co-injection of mst1ra+mstr1rb did produce a 
hemorrhagic phenotype. The dose-dependent response that occurred with the mst1ra+b MO as 
compared to the control MO is evident in Figure 3.37. At a 3 ng dose, 6.67% of mst1ra+b MO 
injected embryos displayed a hemorrhagic phenotype as compared to the 1.61% of control 
morphants with hemorrhages. The prevalence of hemorrhages increased to 13.46% in mst1ra+b 
morphants when the MO dose was increased to 9 ng (Table 3.7).  
 Due to the dose-dependent response that occurred in mst1ra+b morphants, the dose of 
MO was increased to 12 ng, and embryos were co-injected with p53. When co-injected with p53, 
mst1ra+b morphants did not produce a significant hemorrhage phenotype as compared to 
controls (p=0.578). The chi-square statistic with Yates correction was 0.309 with a p-value of 
0.578. Instead, co-injection with p53 resulted in a substantial decline of hemorrhages in 















mst1rab MO 3 ng 15 1 6.67% 
mst1rab MO 9 ng 52 7 13.46% 
mst1rab + p53 MO 12 ng 62 2 3.22% 
hal MO 3 ng 39 3 7.69% 
hal MO 9 ng 12 1 8.33% 
hal + p53 MO 12 ng 43 6 13.95% 
Control MO 9 ng 62 1 1.61% 
p53 MO 12 ng 116 1 0.86% 
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Figure 3.37. Impact of mst1r knockdown on zebrafish vasculature 
The top images (A and B) show zebrafish embryos 48 hours post fertilization that were injected 
with various doses of control MO (A) or mst1r MO (B). The difference in hemorrhage prevalence 







 MO-mediated HAL knockdown was carried out the same way as the previous MO 
knockdowns. Embryos were first injected with either hal MO or control MO to see if a 
hemorrhagic phenotype was observed. At a 3 ng dose of hal MO, 7.69% of embryos had 
hemorrhages, whereas only 1.61% of embryos injected with control MO displayed a 
hemorrhagic phenotype. Increasing the dose of hal MO to 9 ng, increased the percentage of 
embryos with hemorrhages to 8.33% (Table 3.7).  
 Once an observable hemorrhagic phenotype was observed in hal morphants, the MO dose 
was increased to 12 ng, and embryos were co-injected with p53. At a 12 ng dose, the difference 
in hemorrhage prevalence between hal+p53 MO injected zebrafish (13.95%), and p53 MO 
injected control zebrafish (0.86%) was significant (p=0.0017). The chi-square statistic with Yates 
correction was 9.85 with a p-value of 0.0017. Figure 3.38 provides visualization of the dose-
dependent response that occurred, as the concentration of hal MO was increased, the percentage 
of zebrafish embryos with hemorrhages also increased.    
The initial rescue experiment was performed with human RNA concentrations at 200 
ng/ul. At this concentration, both the wildtype and mutant HAL RNA rescued the hemorrhagic 
phenotype. At a 12 ng dose of hal + p53 MO, the prevalence of hemorrhages was 10.26%. 
Embryos that received a subsequent injection of 400 ng wildtype HAL RNA showed a 3.26% 
hemorrhage prevalence, and embryos that received a subsequent injection of 400 ng mutant HAL 
RNA showed a 2.13% hemorrhage prevalence (Table 3.8). The difference in hemorrhage 
prevalence between hal + p53 morphants and hal + p53 morphants with wildtype HAL RNA was 
not significant. The chi-square statistic with Yates correction was 0.668 with a p-value of 0.414. 
Similarly, the difference in hemorrhage prevalence between hal + p53 morphants and hal + p53 
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morphants with mutant HAL RNA was not significant. The chi-square statistic with Yates 
correction was 1.811 with a p-value of 0.178. Furthermore, the difference in hemorrhage 
prevalence between hal + p53 morphants with wildtype HAL RNA and hal + p53 morphants 
with mutant HAL RNA was not significant. The chi-square with Yates correction was 0.186 with 
a p-value of 0.666.  
 The results of the rescue experiment with a diluted RNA concentration (100 ng/ul) 
confirm the specificity of the hal MO induced phenotype and demonstrate the reduced 
functionality of HAL mRNA with the identified variant (Table 3.8). Injection of embryos with 
wildtype HAL RNA, after the injection of hal + p53 MO, rescued the hemorrhagic phenotype. At 
a 12 ng dose of hal + p53 MO, the prevalence of hemorrhages was 12.90%, whereas embryos 
that received a subsequent injection of 200 ng of wildtype HAL RNA had a hemorrhage 
prevalence of 1.61% (Figure 3.39). There was a significant difference in hemorrhage prevalence 
between hal + p53 morphants and hal + p53 morphants with wildtype HAL RNA. The chi-square 
statistic with Yates correction was 10.124 with a p-value of 0.00146.  Embryos that instead 
received a subsequent injection of 200 ng of mutant HAL RNA demonstrated a hemorrhage 
prevalence of 12.77%. This was not statistically different than the hemorrhage prevalence of hal 
+ p53 morphants. The chi-square statistic with Yates correction was 0.0227 with a p-value of 
0.880. There was also a significant difference in hemorrhage prevalence between hal + p53 
morphants with wildtype HAL RNA and hal + p53 morphants with mutant HAL RNA. The chi-
square with Yates correction was 10.218 with a p-value of 0.00139. The control cohort that did 
not receive any MO or RNA injections had a hemorrhage prevalence of 0.94% (Table 3.8). 
Figure 3.40 provides a visualization of the morphant embryos from the rescue experiment.  




























Dose of MO (ng)




























Figure 3.38. Impact of hal knockdown on zebrafish vasculature 
The top images (A and B) show zebrafish embryos 48 hours post fertilization that were injected 
with various doses of control MO (A) or hal MO (B). The difference in hemorrhage prevalence 
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Figure 3.39. Hemorrhage prevalence in rescue experiment with diluted RNA concentration 
The hemorrhage prevalence in uninjected embryos was 0.94 %. At a 12ng dose of hal + p53 MO, 
the prevalence of hemorrhages was 12.90%. Embryos that received a subsequent injection of 200 
ng of wildtype hal RNA had a hemorrhage prevalence of 1.61%. Embryos that instead received a 
subsequent injection of 200 ng of mutant hal RNA demonstrated a hemorrhage prevalence of 
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Figure 3.40. Morphant embryos in rescue experiment 
All images show zebrafish embryos at 48 hours post fertilization. The top left image (A) shows an 
embryo injected with hal+p53 MO. The top right image (B) shows an embryo injected with 
mutant HAL RNA and hal+p53 MO. The bottom left image (C) shows an embryo with wildtype 
HAL RNA and hal+p53 MO. The bottom right image (D) shows an uninjected control embryo. 
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3.7.5 Conservation Between Orthologous Genes  
To better understand why HAL was the only candidate gene that produced a significant 
hemorrhagic phenotype, the level of conservation between orthologous genes at the protein 
domain level was considered (Figure 3.41). Information provided by the National Center for 
Biotechnology Information (NCBI) was used to compare the protein domains of each candidate 
gene across human, mouse and zebrafish species. The name and function of each domain, 
according to the NCBI, is included in Figure 3.41. All protein domains were conserved across 
species for both HAL and METTL20. The majority of protein domains for MST1R were 
conserved between human and mouse species, with the exception of the IPT plexin repeat 1 
domain. However, there were no protein domains depicted for MST1R in zebrafish. Furthermore, 
there were also no protein domains described for ADGRV1 in zebrafish or mouse species. 
The HAL and METTL20 protein domain conservation across species could indicate the 





DUF3534 – N-terminal of Par3 and HAL proteins 
hutH – histidine ammonia-lyase 













Nnt – predicted nicotinamide N-methyase 
 255 
xc 
     
1400 
xc 
IPT – ig-like, plexins, transcription factors 
IPT plexin repeat 1 – first repeat of the IPT domain of plexins and cell surface receptors 
Sema_RON – sema domain, protein interacting module of RON receptor tyrosine kinase 
PSI – domain found in plexins, semaphorins and integrins 
IPT plexin repeat 2 – second repeat of the IPT domain of plexins and cell surface receptors 
PTKc Met Ron – Catalytic domain of the protein tyrosine kinases, met and ron 
MST1R 





                               6306 
xc 
ADGRV1 
GPS – GPCR proteolysis site 
Caca – sodium/calcium exchanger 
Laminin – concanavalin A-like lectin/glucanases superfamily 
Calx-beta – calx beta domain 
EPTP – EPTP domain 
7tm GPCRs – seven-transmembrane G protein-coupled receptor superfamily 
Figure 3.41. Level of conservation between orthologous genes 
Analysis of conserved protein domains across species was performed using data from NCBI. The 
human gene for each candidate was compared to all copies of the mouse and zebrafish genes. There 
were no protein domains depicted for MST1R in zebrafish. There were no protein domains described 





4.1 Reflections on Current Literature 
The emergence of NGS has shifted the focus of many studies investigating the genetic 
component of IA from the initial linkage analyses and GWAS to the newer WES. Although these 
new techniques have been able to identify several different IA candidate genes, progressing this 
list of potential candidates into a definitive contributor to IA development has remained a 
challenge 92,243. The difficulties associated with classifying genetic variants as causative is 
multifactorial; however, there is also a distinct lack in functional analyses accompanying WES 
studies of IA 243. The impact a candidate variant may have on IA development cannot be 
determined without first investigating its functional significance. As NGS technologies continue 
to advance and WGS becomes more accessible, genetic research into IA development will likely 
follow. Expansion to WGS will broaden the search for genomic variations, but similar challenges 
in narrowing candidate variants may persist.  Gene-environment interactions are another 
confounding variable that likely contributes to the lack of causative genes identified in IA 
development. Although risk factors such as smoking and hypertension are well-documented 




Validation of 18 candidate variants was completed via Sanger sequencing, and segregation 
analysis identified six variants from five genes (ZNF835, METTL20, ADGRV1, MST1R, and 
HAL) that met segregation criteria. ZNF835 has no clear orthologue in the zebrafish genome, and 
therefore functional analysis was completed on the four other candidate genes. MO-mediated 
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gene knockdown revealed the loss of METTL20 or ADGRV1 orthologs in a zebrafish model does 
not produce a significant hemorrhagic phenotype. Thus suggesting they are not likely involved in 
zebrafish vascular stability. Functional analysis of MST1R initially revealed a hemorrhagic 
phenotype, but this phenotype was not apparent with the co-injection of p53. Alternatively, MO 
knockdown of hal demonstrated a dose-dependent hemorrhagic phenotype that could be rescued 
by wildtype HAL RNA. The HAL gene was previously recognized as a candidate IA gene, and 
the variant HAL (c.959C>T; p.T320M) segregated with all affected family members in Family 
R1262. Furthermore, HAL (c.959C>T; p.T320M) was predicted deleterious by 6/7 bioinformatic 
tools. The results of Sanger sequencing and functional analysis together provide confidence that 
the HAL (c.959C>T; p.T320M) variant is relevant to the development of IA in Family R1262. 
However, more evidence is needed to prove that HAL is pathogenically relevant in IA.  
 
4.3 Selection of Variant Filtering Criteria  
To prioritize the large number of variants identified via WES, the filtering strategy 
implemented had very stringent exclusion criteria. Determining the best approach to sort through 
WES data can be challenging with such a large number of genetic variants generated. The 
strategy that was ultimately developed aimed to use well-known filtering criteria that did not 
make any assumptions based on a gene’s biological relevance. The filtering criteria implemented 
excluded any non-coding and synonymous variants, to prioritize variants assumed to be more 
likely pathogenic. Although an effective filtering strategy, it is possible that synonymous variants 
may have a role in IA development. The impact of synonymous variants on protein has become 
increasingly apparent, and their role in other human diseases such as melanoma and cystic 
fibrosis has been established 182,244,245. Furthermore, the importance of noncoding regions of the 
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genome in disease development has become more evident in recent years 183,246. Noncoding 
regions are understood to house key elements of gene regulation, such as promoters and 
enhancers, that undoubtedly play a role in human disease. Many Mendelian disorders are still 
unexplained despite the use of WES, and thus recent studies have redirected their focus to 
consider the contribution of noncoding regions of the genome 183,246. The exclusion of variants 
with a MAF greater than 1% is another characteristic of many WES studies. Rare genetic 
variants are presumed more likely to be involved in human disease than those that are more 
common 247. Alternatively, some WES studies of IA have utilized a less stringent 5% allele 
frequency cut-off. While a MAF of less than 5% was initially applied to the variants generated 
from WES within this study, a more stringent filtering criterion was required. Thus a MAF of 
less than 1% was ultimately used. The use of seven different variant pathogenicity prediction 
tools in the variant filtering strategy was implemented based on recommendations from TCAG. 
Although these bioinformatic pipelines are widely used in the filtering of WES data, some 
studies suggest multiple tools are required to offset the low specificity of certain tools 248. The 
filtering criteria used in this project required variants to be predicted pathogenic by 4/7 of 
bioinformatic tools. Future studies could adjust this ratio to construct a more or less stringent 
strategy. To evaluate potentially pathogenic variants in families where no variants of interest 
have been identified, future studies may restructure the current filtering strategy. Relaxation of 
some of the previously used filtering criteria could broaden the group of candidate variants. Such 
stringent filtering criteria may have eliminated pathogenic variants involved in IA development.  
 Even after the implementation of the stringent filtering strategy, further prioritization of 
the remaining variant list was still required. When potential prioritization strategies were being 
explored, the WES studies by Farlow et al. (2015) and Yan et al. (2015) were fairly recent IA 
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studies that published lists of candidate IA genes. Prioritizing variants in previously reported 
candidate IA genes was an efficient way to decide which variants should be validated with 
Sanger sequencing 15. As the definitive pathophysiology behind IA development has yet to be 
solidified, the objective was to avoid making premature assumptions based on only gene 
function. Although there were six variants prioritized from this phase of the filtering strategy, the 
resources were available to investigate additional candidates. The reduced genetic heterozygosity 
of the NL population reinforces the possibility that highly penetrant pathogenic variants in a 
single gene may predispose to IA in more than one family. Therefore, variants shared in multiple 
families were also prioritized. Ultimately, 18 variants were selected for validation with Sanger 
sequencing. Deciding on the most appropriate variant filtering strategy can be extremely 
challenging, primarily due to the copious amount of data generated from WES. Thus, a more 
stringent filtering approach was decided to be the most appropriate place to start. Future studies 
could relax some filtering criteria, disregard the significance of genes reported in previous IA 
studies, or place more importance on the functional relevance of genes. Gene expression data is 
another criterion that could be utilized in future endeavours. While this project did not filter 
variants based on a gene’s biological relevance, many databases exist that provide lists of genes 
relevant to brain physiology. Databases such as BrainEXP or The Human Protein Atlas could be 
used in future studies to include gene expression data when implementing a variant filtering 
strategy 249–251.  
 
4.4 Variant Segregation Analysis  
When analyzing variant segregation after Sanger sequencing, only variants found within the 
exomes of all affected individuals within a family were considered for further functional 
 169 
analysis. Such stringent segregation criteria assumes that all IAs within a family are the result of 
the same pathogenic variant. This strategy does not acknowledge any possible phenocopies or 
environmental contributions to IA development. Future studies may consider including variants 
shared by all but one affected individual within a family, but for this project, more stringent 
criteria were used. 
If variants were found in all affected individuals within a family, unaffected relatives were 
also sequenced to evaluate variant segregation further.  The use of unaffected relatives in variant 
prioritization in studies of IA can be challenging. The late-onset nature of IA makes it difficult to 
classify an individual as truly unaffected as they may eventually develop an IA. To be considered 
unaffected within the study, individuals had to be screened to confirm no IA was present. 
However, some individuals were well below the average age of IA onset. Although not used as a 
definitive filter, considering the age of seemingly unaffected individuals when analyzing variant 
segregation did introduce some subjectivity.  Furthermore, it’s unlikely that all individuals 
carrying a causative genetic variant will display the corresponding phenotype, and thus 
incomplete penetrance should be taken into account. For these reasons, the presence of a 
candidate variant in a seemingly unaffected individual was not grounds for exclusion from 
further functional analysis. Instead, the familial segregation for each variant was analyzed 
independently with the requirement that prioritized variants were absent from a large percentage 
of unaffected relatives.  
Family R1262 was of particular interest within this study due to the strong history of both IA 
and AAA. Variant identification within unaffected relatives could not be used as an exclusion 
criterion within this family as there were only affected study participants. With one less filtering 
criterion applied to potential candidate variants within this family, a higher number of candidate 
 170 
variants may have resulted as compared to other families. However, to compensate for the lack 
of unaffected study participants within Family R1262, once HAL (c.959C>T; p.T320M) emerged 
as the primary variant of interest, 200 additional population controls were Sanger sequenced.  
 
4.5 Implications of Functional Analysis Results  
Although Sanger sequencing results ultimately identified six variants from five genes (HAL, 
ZNF835, MST1R, METTL20, and ADGRV1) that met segregation criteria, ZNF835 has no clear 
orthologue in the zebrafish genome. Therefore functional analysis was completed on the four 
other candidate genes.  
The nonsynonymous SNV METTL20 (c.583C>G; p.L195V) was initially deemed a candidate 
variant of interest. Segregation analysis revealed it segregated with all affected individuals in two 
unrelated NL families, R1385 and R1277. Sequencing of unaffected relatives showed the variant 
was found in 1/8 unaffected relatives in Family R1277 (Z1359) but was also present in the one 
unaffected study participant in Family R1385 (Z1149). The CT scans of both Z1359 and Z1149 
were completed when these participants were slightly younger than the average age of IA onset, 
and thus functional analysis was still completed. The MO-mediated knockdown of the METTL20 
zebrafish ortholog did not produce a significant hemorrhagic phenotype at two different MO 
doses compared to that of controls. These results do not support the involvement of the 
METTL20 gene in zebrafish vascular stability, and alternative genetic contributions should be 
considered for these families.  
Functional analysis into ADGRV1 produced similar results to those of METTL20. The 
ADGRV1 gene has been previously associated with familial febrile seizures and Usher syndrome, 
a disorder characterized by vision and hearing loss 234,235. There were two different variants 
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within this gene that were found in two unrelated NL families. The variant ADGRV1 
(c.1522A>C; p.I508L) segregated with both affected individuals in Family R1262 and the variant 
ADGRV1 (c.6317C>T; p.A2106V) segregated with all affected individuals in Family R1276 and 
was found in only 2/52 unaffected study participants. The extensive number of unaffected study 
participants recruited within Family R1276 is due to the initial classification of Z1415 as an 
affected family member. Subsequent investigations revealed that Z1415 is an unaffected 
individual who does not carry the ADGRV1 (c.6317C>T; p.A2106V) variant. Taking a closer 
look at the unaffected carriers of ADGRV1 (c.6317C>T; p.A2106V), specifically Z1027, 
produced some interesting results. The strong family history of IA is from the maternal side of 
the family (relative to Z1027). The mother of Z1027, Z1021, is also an unaffected study 
participant, but she does not carry the ADGRV1 (c.6317C>T; p.A2106V) variant. Sanger 
sequencing was completed multiple times on DNA from Z1027 to confirm the presence of 
ADGRV1 (c.6317C>T; p.A2106V). The father of Z1027 is not a study participant. While the 
possibility remains that ADGRV1 (c.6317C>T; p.A2106V) was transmitted paternally to Z1027, 
a sample mix-up during DNA extraction is another plausible explanation and can occur at a rate 
>1%. The lack of a significant hemorrhagic phenotype with the genetic knockdown of the 
ADGRV1 zebrafish ortholog does not provide confidence that this gene is contributing to 
vascular stability in zebrafish.  
The predicted impact of MST1R (c.4129C>T; p.Q1377X) as a stopgain mutation made it an 
enticing candidate from the beginning. Furthermore, this was a novel variant not previously 
described and was found to segregate with all affected individuals in two unrelated NL families, 
R1262 and R1385. The only unaffected study participant within Family R1381, Z1149, was also 
a carrier of MST1R (c.4129C>T; p.Q1377X) but again was only 41 years old at the time of her 
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last CT scan. Non-IA phenotypes are also associated with the MST1R gene. Increased expression 
of MST1R has been noted in many epithelial neoplasms, and WES has identified it as a 
susceptibility gene in nasopharyngeal carcinoma 252–254. During the initial stages of functional 
analysis, MST1R still appeared to be a favorable candidate gene in IA development. The co-
injection of mst1ra+b produced a dose-dependent hemorrhagic phenotype at the two lowest 
doses of MO (3 ng and 9 ng). To avoid the off-target effects observed at higher doses of MO, 
embryos were co-injected with p53 when the dose of MO was increased. The possible 
contribution of MST1R mutations to IA development became less plausible as mst1ra+b 
morphants did not produce a significant hemorrhage phenotype when co-injected with p53. 
These results suggested that the initially observed phenotype was not specific to the mst1ra+b 
knockdown and instead was due to off-target effects of p53. These results did not produce 
confidence moving forward that MST1R (c.4129C>T; p.Q1377X) is a causative variant in IA 
development. Consequently, HAL became the only remaining candidate gene of interest. While 
the HAL gene became the focus of further investigations, it is important to recognize that the 
absence of a visible hemorrhagic phenotype in zebrafish morphants cannot definitively rule out 
the contribution of a gene to IA development. The results from this project do not support a role 
for METTL20, ADGRV1, or MST1R in the vascular stability of zebrafish, but further 
investigations are required to examine their connection to human IA.  
 The HAL gene was initially highlighted as a candidate IA gene by Farlow et al. (2015) 
who performed WES on 45 individuals affected with IA that were recruited as part of the FIA 
study. The variant HAL (c.G1472T; p.G491V) was prioritized after meeting all variant filtering 
criteria and segregated with IA in one of the seven study families. An alternative variant was 
identified in Family R1262, HAL (c.959C>T; p.T320M), that segregated with all affected family 
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members. The HAL (c.959C>T; p.T320M) variant was identified in 1/300 NL population 
controls, a slightly higher prevalence than the 0.024% MAF reported by ExAC. While it is 
possible HAL (c.959C>T; p.T320M) is more prevalent in the NL population, it is also a 
possibility this individual has an IA. The population controls were available from the NFCCR 
and were never screened for IAs.  
Once functional analysis began, knockdown of the HAL zebrafish ortholog at lower MO 
doses produced an observable hemorrhagic phenotype. The dose of hal MO was subsequently 
increased, embryos were co-injected with p53 MO, and a significant dose-dependent 
hemorrhagic phenotype was still observed. Although these results indicate that the hemorrhagic 
phenotype was not due to off-target effects of p53, previous research suggests that co-injection 
of p53 alone is not enough to ensure a phenotype is gene specific, and additional control 
measures should be taken 140,142. The results of the RNA rescue experiment confirm the 
specificity of the hal MO. Injection of wildtype human HAL RNA in the hal MO background 
was able to rescue the hemorrhagic phenotype. This demonstrates that there must be some 
functional overlap between human and zebrafish HAL as human RNA can rescue the zebrafish 
phenotype. The mutant HAL RNA was not able to rescue the morpholino phenotype, suggesting 
that the variant causes a change in protein function. During the initial rescue experiment, RNA 
concentrations of 200 ng/ul resulted in both the wildtype HAL RNA and mutant HAL RNA to 
rescue the hemorrhagic phenotype. Such a high concentration of RNA is much greater than the 
physiologic levels typical of a zebrafish embryo. Overloading the embryo with excess RNA 
could result in both wildtype and mutant RNA rescuing the phenotype, assuming that the variant 
does not generate a null allele. Once the experiment was repeated with a diluted RNA 
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concentration (100 ng/ul) at 200 ng/embryo, it became apparent that only the wildtype HAL 
RNA was able to rescue the hemorrhagic phenotype.  
The phenotype observed in all MO-mediated gene knockdown experiments completed 
throughout this project was hemorrhaging within the zebrafish and not the development of IAs 
specifically. This lack of aneurysm development was a drawback discussed by Santiago-Sim et 
al. (2016) and is not specific to this project 105. There was no aneurysm development observed in 
their mouse or zebrafish knockdowns, and instead, a cerebral hemorrhage phenotype was 
observed 105. They suggested that as is the case with humans, small IAs often go unnoticed. The 
size of an IA may render it indistinguishable, but it is also possible that zebrafish do not develop 
aneurysms at all, and weakening of the vasculature instead leads to a hemorrhagic phenotype 105. 
A lack of visible aneurysm in this model system makes it challenging to determine the clinical 
significance of the variants that have been identified. The vascular dysfunction that was 
demonstrated in HAL morphants could potentially represent the vascular dysfunction that is 
involved in human IA development, but further functional work is needed to confirm this. 
Furthermore, the hemorrhages produced by hal knockdown were not always localized to the 
head of the zebrafish. Hemorrhages identified within the body of the zebrafish were also 
considered a hemorrhagic phenotype. In humans, the co-occurrence between AAA and IA has 
been widely recognized but not well understood. With such a strong family history of IA and 
AAA in Family R1262, the same genetic variant underlying IA development could also be 
contributing to AAA development. The results of the functional analysis, as well as the rescue 
experiment, suggest that HAL (c.959C>T; p.T320M) could be contributing to IA development in 
Family R1262. Future research is needed to investigate the mechanism underlying HAL function 
and assess the broader contribution of HAL mutations to aneurysm formation.  
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4.6 Limitations 
The many appealing aspects of WES that have been very beneficial in gene discovery 
also underlie many of the challenges associated with this technology. By using of WES, all 
genetic variants within an individual’s exome can be identified. However, even after initial 
filtering steps thousands of genetic variants remained. The challenge becomes determining an 
appropriate filtering approach that is stringent enough to narrow the search while still broad 
enough to not prematurely exclude possible candidates. There are also limitations associated 
with exome sequencing coverage itself. Although the majority of Mendelian diseases have been 
identified in the protein-coding region of the genome, this still only makes up a small proportion 
of the human genome. Data generated from WES will not be able to identify genomic variations 
outside this region that may be contributing to IA development. The current study design was 
based on the assumption IA follows a monogenic model of inheritance. But the possibility 
remains that a much more complex inheritance pattern involving the interaction of multiple 
genes could be contributing to IA development in some families. Various environmental risk 
factors such as smoking, and hypertension have also been documented in many study 
participants that could be contributing to the development of IA. These risk factors were not 
considered when analyzing segregation data, yet they may have had a significant impact on IA 
formation in some patients.   
While this project had numerous large, well-documented families available, there is a 
lack of recent clinical follow-up data available. The majority of CT scans performed on these 
participants were completed almost ten years ago. Many seemingly unaffected individuals at the 
time of screening may have since developed IA, and thus follow-up data would have been 
beneficial for segregation analysis. Clinical data regarding known IA risk factors such as 
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smoking and hypertension were recorded during participant recruitment. However, this data was 
not significantly considered throughout the study, as only minimal details were available. More 
detailed, and up to date clinical data could have helped distinguish possible phenocopies during 
segregation analysis.  
The controls used in this project were from the NFCCR. The only information available 
about these individuals is that participants had no known personal or family history of cancer. 
Ideally, population controls would have been recruited exclusively for this project. However, 
financial constraints made NFCCR controls the next best option. Future studies could look at 
sequencing an additional number of controls to increase accuracy or recruit controls specific to 
the project.   
 In addition to the advantages of using zebrafish as a functional model of IA development, 
there are also limitations specific to a morpholino-based technique. Significant dosage based, 
off-target effects have been consistently seen at high doses of MO 201. Although specific 
precautions were followed to ensure accurate functional analysis, such as co-injection with p53, 
possible off-target effects should always be considered when using MOs. Furthermore, it cannot 
be disregarded that a limited number of studies have used MO-mediated gene knockdown to 
investigate an IA phenotype specifically. Therefore, it is important to be aware of the possible 
challenges in relying on a zebrafish as the sole functional model, and additional functional assays 
should be explored.  
 
4.7 Future Directions 
Due to the inability to complete MO-mediated gene knockdown of ZNF835 (c.378delC; 
p.I126fs) within this project, an alternative method of functional analysis would be worth 
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pursuing in future investigations. There is limited information available about the functional 
relevance of the ZNF835 gene. However, it was identified as a candidate IA gene by Farlow et 
al. (2015) and a novel frame-shift deletion that segregated with all affected individuals was 
identified in Family R1381. The only seemingly unaffected relative identified to have the 
ZNF835 (c.378delC; p.I126fs) variant was only 25 at the time of his last CT scan. Without any 
more recent clinical data, it is difficult to know that he is truly unaffected. The identification of a 
novel variant within a previously identified candidate gene, combined with the variant 
segregation within Family R1381, resulted in ZNF835 (c.378delC; p.I126fs) as the initial 
favorable candidate. Future investigations should explore alternative functional investigations for 
ZNF835 as it is becoming increasingly clear that multiple variants, in different genes, are likely 
contributing to IA within different families.  
To examine the HAL (c.959C>T; p.T320M) variant frequency within the general NL 
population, Sanger sequencing was completed on 300 population controls. However, the larger 
contribution of HAL to IA formation could also be investigated by sequencing unrelated IA 
probands for the HAL (c.959C>T; p.T320M) variant or any other potentially pathogenic variants 
within this gene. Future studies could also use statistical analysis to provide valuable insight into 
the likelihood HAL (c.959C>T; p.T320M) is relevant to IA development.  
Additionally, the involvement of HAL in histidine catabolism could be the focus of future 
investigations. Histidine ammonia-lyase catalyzes the conversion of l-histidine to urocanate, and 
thus, a loss of function HAL variant can result in excess levels of histidine (histidinemia). Most 
patients with histidinemia are thought to be asymptomatic. However, as an essential amino acid 
that crosses the blood-brain barrier, histidine may have many additional functions not yet 
established 227,228. Histidinemia can be identified by measuring the histidine concentration in a 
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blood or urine sample. Consequently, future projects could measure histidine levels to determine 
if the HAL (c.959C>T; p.T320M) variant causes an increased concentration of histidine in 
affected individuals. Furthermore, other intermediates in histidine catabolism could also be 
explored in future projects to help clarify histidine's role in IA development.  
Guidelines on the use of MOs in zebrafish provide many suggestions that could be the focus 
of future directions to verify the contribution of HAL mutations in IA development. Ideally, 
morphant phenotypes would be compared to mutant phenotypes generated via genome–editing 
tools. Such tools include CRISPR/CAS9 or Transcription Activator–Like Effector Nucleases 
(TALEN) 142. Future studies could aim to generate a mutant line using a genome-editing tool. 
Mutant phenotypes could then be assessed to ensure the MO induced morphant phenotype is 
similar and not more severe. Another validation suggestion that was recently described is the use 
of multiple MOs 142. Future studies could use a HAL MO targeted to an alternative 
oligonucleotide sequence or use a translation blocking MO in addition to the splice blocking type 
used in this project. Functional analysis of HAL in a different animal model is another future goal 
of the project. This could provide additional evidence that HAL knockdown results in a 
hemorrhagic phenotype.  
Although the results of this study provide evidence that HAL (c.959C>T; p.T320M) could be 
contributing to IA development in Family R1262, there are twelve other families within this 
cohort, without HAL variants. Likely multiple genes are contributing to IA development, and 
future studies could use a similar project framework with a modified variant filtering strategy. 
Another possibility includes looking for a genetic contribution outside the exome by employing 
the use of whole genome sequencing analysis. Furthermore, the impact of environmental factors 
on IA development should not be overlooked. Underlying factors, in addition to those previously 
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identified, such as smoking, hypertension, and alcohol consumption, may have a much more 
significant impact on IA development than what is currently presumed. 
 
4.8 Conclusions 
Focusing on a large cohort of multiple NL families with a strong genetic predisposition to IA, 
this project was able to identify a potentially pathogenic variant relevant to the development of 
IA. The variant filtering strategy that was implemented in 43 individuals affected with IA across 
13 NL families identified 18 candidate variants. With the use of Sanger sequencing, segregation 
analysis of all 18 variants identified five candidate genes worth pursuing further functional 
analysis. Without a clear zebrafish ortholog, ZNF835 was not able to undergo functional 
analysis; however, ZNF835 (c.378delC; p.I126fs) remains an exceptional candidate variant in IA 
development worth pursuing in future studies. The MO-mediated gene knockdown of ADGRV1, 
METTL20, MST1R, and HAL established that hal morphants demonstrate a dose-dependent 
hemorrhagic phenotype that can be rescued with wildtype HAL RNA. These results suggest that 
the HAL (c.959C>T; p.T320M) variant could be contributing to IA development in Family 
R1262. Future analysis of the HAL gene could be beneficial in determining the extent of its 
involvement in IA development and contribute to an improved understanding of IA 
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Appendix A – Primer Sequences 
 

















































































Appendix B – Thermal Cycler Protocols 
Step Temperature (°C) Duration 
Standard PCR 
1 95 5 minutes 
2a 95 30 seconds 
2b Annealing Temp 30 seconds 
2c 72 1 minutes 
3 - Return to step 2 (30 cycles) 
4 72 7 minutes 
5 4 Hold 
Touchdown A 
1 95 2 minutes 
2a 95 20 seconds 
2b 67* 45 seconds 
2c 72 45 seconds 
3 - Return to step 2 (14 cycles) 
4a 95 20 seconds 
4b 60 45 seconds 
4c 72 45 seconds 
5 - Return to step 4 (19 cycles) 
6 72 5 minutes 
7 4 Hold 
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ExoSAP 
1 37 30 minutes 
2 80 15 minutes 
3 4 Hold 
ABI Sequencing 
1 96 1 minute 
2a 96 10 seconds 
2b 50 5 seconds 
2c 60 4 minutes 
3 - Return to step 2 (24 cycles) 
4 4 Hold 
Denature 
1 95 2 minutes 
2 4 Hold 
 
* After the initial cycle the annealing temperature is decreased by 0.5°C increments for 
subsequent cycles 
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Appendix C – 20X Embryo Media Recipe 
- 17.5g NaCl 
- 0.75g KCl 
- 2.9g CaCl-2H2O 
- Add MiliQ water to 800ml 
- 0.41g KH2PO4 
- 0.142g Na2HPO4 anhydrous 
- 4.9g MgSO4-7H2O 
- Add MiliQ water to 1 liter 
- Vacuum filter 
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